var docs;if (!docs) docs =[]; docs["100"]={"10009":"<p><b>Title</b> Blood Pressure Lowering Agents / Alfuzosin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hypotension, postural hypotension, and syncope if alfuzosin is combined with blood pressure lowering agents. Patients should be warned of the possibility of these events and should avoid situations in which syncope could result in injury.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Alfuzosin prescribing information states that alfuzosin may cause postural hypotension and that the risk of this adverse effect may increase when alfuzosin is combined with other medications known to lower blood pressure.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Uroxatral (alfuzosin) [prescribing information]. Cary, NC: Covis Pharmaceuticals Inc; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10010":"<p><b>Title</b> Amifostine / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When amifostine is used at doses recommended for chemotherapy, blood pressure lowering agents should be withheld for 24 hours prior to amifostine administration to avoid excessive hypotension during or immediately after infusion. If blood pressure lowering agents cannot be withheld, then amifostine should not be administered. Caution is recommended when using amifostine at the lower doses recommended for radiotherapy, but routine interruption of blood pressure lowering agent therapy is not recommended in these patients.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> In clinical trials in which amifostine was used at chemotherapy doses (i.e., 910 mg/m<sup>2</sup>) the incidence (per patient) of hypotension (all severity grades) was 61%, with an incidence of severe hypotension (requiring interruption of infusion and/or a pressure drop of at least 20mmHg) of 8%.<sup>1</sup> In comparison, data from trials in which amifostine was used at radiotherapy doses (i.e., 200mg/m<sup>2</sup>) the overall incidence of hypotension was 15%, and the incidence of severe hypotension was 3%. In order to decrease the risk of excessive hypotensive reactions, amifostine prescribing information recommends temporarily withholding blood pressure lowering medications for 24 hours prior to amifostine administration.<sup>1</sup> If blood pressure lowering therapy cannot be withheld, then amifostine should not be administered.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ethyol (amifostine) [prescribing information]. Bedford, OH: BenVenue Inc; November 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10011":"<p><b>Title</b> Blood Pressure Lowering Agents / Brimonidine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Brimonidine (Topical) may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for excessive hypotension when topical brimonidine is used in patients taking blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The prescribing information for topical brimonidine states that concurrent use with blood pressure lowering agents may result in excessive systemic brimonidine effects such as hypotension, bradycardia, and/or CNS depression.<sup>1</sup><br><br>A study evaluating the cardiovascular effects of ophthalmic brimonidine, compared to ophthalmic timolol (0.5%) and betaxolol (0.25%) found that brimonidine reduced systolic blood pressure by 5.2 to 7.3 mmHg more than timolol or betaxolol (n=24 healthy volunteers).<sup>2</sup><br><br>One published report describes two infants who experienced bradycardia, hypotension, and CNS depression that was attributed to the concurrent use of ophthalmic brimonidine and a beta-blocker.<sup>3</sup> Though not specifically describing an interaction, other case reports describe systemic effects (unresponsiveness, altered mental status, hypotension, bradycardia) attributed to ophthalmic brimonidine when used in pediatric patients.<sup>4,5</sup> An analysis of 30 pediatric patients (mean age = 10.5 years) treated with ophthalmic brimonidine found that 7 patients (23%) experienced systemic effects ranging from fatigue to repeatedly being unarousable following brimonidine administration.<sup>6</sup><br><br>Of note, although use of topical brimonidine does appear to result in some systemic absorption, the prescribing information does not cite any reports of adverse effects consistent with bradycardia, hypotension, or CNS depression.<sup>1</sup><br><br>The likely mechanism for any such interaction is systemic alpha2-agonist actions of absorbed brimonidine leading to additive or synergistic blood pressure lowering effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mirvaso (brimonidine) [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; August 2013.</p>\n<p>2. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. <i>Arch Ophthalmol</i>. 1995;113(1):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7826297\">[PubMed 7826297]</a></p>\n<p>3. Mungan NK, Wilson TW, Nischal KK, Koren G, Levin AV. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. <i>J AAPOS</i>. 2003;7(1):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12690374\">[PubMed 12690374]</a></p>\n<p>4. Rangan C, Everson G, Cantrell FL. Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings. <i>Pediatr Emerg Care</i>. 2008;24(3):167-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18347496\">[PubMed 18347496]</a></p>\n<p>5. Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. <i>J Pediatr</i>. 2001;138(3):441-443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11241061\">[PubMed 11241061]</a></p>\n<p>6. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. <i>J AAPOS</i>. 2001;5(5):281-284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11641636\">[PubMed 11641636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10012":"<p><b>Title</b> Blood Pressure Lowering Agents / Diazoxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diazoxide may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excessive hypotension when diazoxide is combined with blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> With an intravenous formulation of diazoxide (no longer available), several cases of severe hypotension (at times fatal) have been documented following combined use with hydralazine within a few hours of one another.<sup>1,2,3,4</sup> It is presumed that the vasodilatory effects of the two agents were additive, apparently beyond the ability of the body to maintain adequate pressure.<br><br>Prescribing information for the oral diazoxide formulation (labeled for use as anti-hypoglycemic agent) states that blood pressure lowering effects of oral diazoxide are relatively minor, particularly compared with intravenous diazoxide.<sup>5</sup> Despite this reportedly minor hypotensive effect, the prescribing information cautions that oral diazoxide may enhance the hypotensive effects of blood pressure lowering agents.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Henrich WL, Cronin R, Miller PD, Anderson RJ. Hypotensive sequelae of diazoxide and hydralazine therapy. <i>JAMA</i>. 1977;237(3):264-265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=576161\">[PubMed 576161]</a></p>\n<p>2. Miller WE, Gifford RW Jr, Humphrey DC, Vidt DG. Management of severe hypertension with intravenous injections of diazoxide. <i>Am J Cardiol</i>. 1969;24(6):870-875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5360241\">[PubMed 5360241]</a></p>\n<p>3. Mizroch S, Yurasek M. Hypotension and bradycardia following diazoxide and hydralazine therapy. <i>JAMA</i>. 1977;237(23):2471-2472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=576958\">[PubMed 576958]</a></p>\n<p>4. Romberg GP, Lordon RE. Hypotensive sequelae of diazoxide and hydralazine therapy. <i>JAMA</i>. 1977;238(10):1025. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=577939\">[PubMed 577939]</a></p>\n<p>5. Proglycem (diazoxide) [prescribing information]. Miami, FL: IVAX Pharmaceuticals Inc; October 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10013":"<p><b>Title</b> Blood Pressure Lowering Agents / Herbs (Hypotensive Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Herbs (Hypotensive Properties) may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excessive decreases in blood pressure if herbal products with hypotensive properties are used with blood pressure lowering agents.</p>\n<div>\n <p><b>Herbs (Hypotensive Properties) Interacting Members</b> Black Cohosh, California Poppy, Coleus, Goldenseal, Hawthorn, Mistletoe, Periwinkle, QuiNINE, Shepherd's Purse</p>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Many herbal products have been shown to decrease blood pressure in some individuals. <sup>1,2</sup> Concomitant use with drugs that have a similar pharmacologic potential may increase the risk of excessive hypotension. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Richard CL, Jurgens TM. Effects of natural health products on blood pressure. <i>Ann Pharmacother</i>. 2005;39(4):712-720. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15741425\">[PubMed 15741425]</a></p>\n<p>2. Ernst E. Cardiovascular adverse effects of herbal medicines: a systematic review of the recent literature. <i>Can J Cardiol</i>. 2003;19(7):818-827. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12813616\">[PubMed 12813616]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10014":"<p><b>Title</b> Blood Pressure Lowering Agents / Molsidomine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Molsidomine may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when molsidomine is combined with a blood pressure lowering agent, and monitor patients closely for evidence of excessive blood pressure reduction, including evidence of orthostatic hypotension.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Molsidomine labeling states that concurrent use of molsidomine with blood pressure lowering agents may result in enhanced blood pressure-lowering effects.<sup>1,2</sup> Molsidomine works as a nitric oxide donor, encouraging vasodilation and possibly enhancing hypotensive effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Molsidain (molsidomine) [summary of product characteristics]. Barcelona, Spain; Sanofi-Aventis SA; August 2013.</p>\n<p>2. Molsiton (molsidomine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501832. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10015":"<p><b>Title</b> Blood Pressure Lowering Agents / Obinutuzumab</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Obinutuzumab may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In order to minimize the risk of excessive hypotension during or immediately after obinutuzumab infusion, clinicians should consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to infusion and continuing until 1 hour after infusion and until the patient's blood pressure is stable.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Obinutuzumab prescribing information states that 69% of patients receiving obinutuzumab in clinical trials experienced an infusion related reaction during their first infusion of obinutuzumab, with hypotension as one of the reported components of an infusion related reaction.<sup>1</sup> In order to minimize the risk of excessive hypotensive reactions, clinicians should consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after infusion and until the patient's blood pressure is stable.<sup>1</sup> Although the incidence of infusion-related reactions decreased from 69% after the first infusion to 3% after the second infusion and to less than 1% after subsequent infusions, close monitoring of the blood pressure response would still be warranted.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gazyva (obinutuzumab) [prescribing information]. South San Francisco, CA: Genentech Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10016":"<p><b>Title</b> Blood Pressure Lowering Agents / Pentoxifylline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pentoxifylline may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood pressure closely and advise patients of the possibility for enhanced blood pressure lowering with concurrent use of pentoxifylline and blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Pentoxifylline prescribing information states that because small blood pressure reductions have been associated with pentoxifylline use, increased monitoring of blood pressure may be warranted in patients receiving blood pressure lowering medications.<sup>1</sup> Of note, the prescribing information also states that the concurrent use of pentoxifylline with various antihypertensive agents have indicated no problems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trental (pentoxifylline) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10017":"<p><b>Title</b> Blood Pressure Lowering Agents / Phosphodiesterase 5 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy. PDE5 inhibitors can cause additional mild to moderate blood pressure reductions (and related adverse effects, such as dizziness, lightheadedness, and/or fainting), and the magnitude of this effect may vary depending on the blood pressure lowering agent used.</p>\n<div>\n <p><b>Phosphodiesterase 5 Inhibitors Interacting Members</b> Avanafil, Mirodenafil, Sildenafil, Tadalafil, Udenafil, Vardenafil</p>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> As an extension of their pharmacologic effects, phosphodiesterase type 5 (PDE5) inhibitors exert at least some mild systemic vasodilation. Prescribing information for PDE5 inhibitors marketed in the US present data supporting mild to moderate additional blood pressure lowering effects of these agents in patients receiving antihypertensive medications.<sup>1,2,3,4,5,6</sup> Studies of avanafil (200 mg) added to enalapril or amlodipine showed average reductions in supine systolic blood pressure of 1.2 to 1.8 mm Hg and reductions in diastolic blood pressure of 3.5 mm Hg.<sup>6</sup> Mirodenafil and udenafil prescribing information both describe a clinical studies where no clinically significant change in blood pressure was noted in patients receiving antihypertensive therapy, but states that additional blood pressure monitoring should occur if these agents are combined.<sup>7,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cialis (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; April 2009.</p>\n<p>2. Adcirca (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2009.</p>\n<p>3. Levitra (vardenafil) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; June 2008.</p>\n<p>4. Viagra (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; August 2008.</p>\n<p>5. Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; May 2009.</p>\n<p>6. Stendra (avanafil) [prescribing information]. Mountain View, CA: Vivus Inc; April 2012.</p>\n<p>7. Mvix 50 mg tablet (mirodenafil) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200708298. Accessed April 7, 2016.</p>\n<p>8. Paick JS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil in men taking antihypertensive medications. <i>J Sex Med</i>. 2010;7(9):3143-3152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20649936\">[PubMed 20649936]</a></p>\n<p>9. Udenafil 100/200 mg tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200500258. Accessed September 22, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10018":"<p><b>Title</b> Blood Pressure Lowering Agents / Prostacyclin Analogues</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood pressure closely when using a prostacyclin analogue in combination with blood pressure lowering agents.</p>\n<div>\n <p><b>Prostacyclin Analogues Interacting Members</b> Beraprost, Epoprostenol, Iloprost, Treprostinil</p>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Endogenous prostacyclin (PGI<sub>2</sub>) is a potent vasodilator; likewise, prostacyclin analogues are capable of producing significant dilation of pulmonary and systemic vessels.<sup>1,2,3,4</sup> Prescribing information states that the effects of other blood pressure lowering agents may be exacerbated when combined with a prostacyclin analogue.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Remodulin (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; February 2008.</p>\n<p>2. Flolan (epoprotenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2011.</p>\n<p>3. Ventavis (iloprost) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; November 2013.</p>\n<p>4. Berasil (beraprost) [KR summary of product characteristics]. Http://ezdrug.mfds.go.kr/kfda2?cmd=CCBAA02L2&amp;itemSeq=199400456. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10019":"<p><b>Title</b> Antihypertensive Agents / Amphetamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to antihypertensive medications (ie, blood pressure, heart rate) when starting, stopping, or changing the dose of concomitant amphetamines.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Stimulant medications, such as the amphetamines, are known to cause modest increases in average blood pressure (BP) and heart rate (HR). A systematic review of amphetamines in adult patients using amphetamines for recovery from a stroke (2 studies with total of 73 patients) concluded that amphetamines increased systolic BP by 8.4 mm Hg (95% CI: 1.6 to 15.2 mm Hg), diastolic BP by 4.9 mm Hg (95% CI: 1.1 to 8.8 mm Hg), and HR by 10.6 bpm (95% CI: 3.3 to 17.8 bpm). However, it was unclear how many of these patients had a prior history of hypertension and how many were also receiving antihypertensive medication(s).<sup>1</sup><br><br>In a more directly applicable study, 13 adult patients with treated essential hypertension and attention-deficit/hyperactivity disorder were treated with amphetamines for 6 weeks and then followed for an additional 2 weeks off of treatment.<sup>2</sup> ACE inhibitors, thiazide diuretics, beta-blockers, and calcium channel antagonists were the antihypertensives used. Neither mean blood pressure nor heart rate increased significantly from baseline to week 6 (SBP: 120.6 vs 117.1 mm Hg; DBP: 80.5 vs 81.1 mm Hg; HR: 75.2 vs 78.0 bpm; respectively). Additionally, no patients experienced a blood pressure greater than 140/90 mm Hg on 2 consecutive visits during the study period, with a total of 3 single episodes of SBP greater than140 mm Hg and/or DBP greater than 90 mm Hg during the study. Unlike reports from patients without hypertension or with an unclear blood pressure history, this small study suggests that amphetamines do not significantly decrease the effectiveness of antihypertensive medications in patients with hypertension.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Matinsson L, Hardemark H, Eksborg S. Amphetamines for improving recovery after stroke. <i>Chochrane Database Syst Rev</i>. 2007;(1):CD002090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17253474\">[PubMed 17253474]</a> </p>\n<p>2. Wilens TE, Zusman RM, Hammerness PG, et al. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. <i>J Clin Psychiatry</i>. 2006;67(5):696-702. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16841618\">[PubMed 16841618]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10020":"<p><b>Title</b> Antihypertensive Agents / Herbs (Hypertensive Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Herbs (Hypertensive Properties) may diminish the antihypertensive effect of Antihypertensive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of antihypertensive therapy if used with an herb possessing hypertensive potential.</p>\n<div>\n <p><b>Herbs (Hypertensive Properties) Interacting Members</b> Bayberry, Blue Cohosh, Cayenne, Ephedra, Ginger, Ginseng (American), Kola Nut, Licorice</p>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Many herbal products have been shown to increase blood pressure in some individuals.<sup>1</sup> Concomitant use with drugs used to decrease blood pressure may decrease the therapeutic efficacy of the antihypertensive. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jalili J, Askeroglu U, Alleyne B, Guyuron B. Herbal products that may contribute to hypertension. <i>Plast Reconstr Surg</i>. 2013;131(1):168-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23271526\">[PubMed 23271526]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10021":"<p><b>Title</b> Antihypertensive Agents / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may diminish the antihypertensive effect of Antihypertensive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When using methylphenidate in patients being treated for hypertension, monitor blood pressure response closely when starting methylphenidate or during dose adjustments.</p>\n<div>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Several studies in both adults and children with ADHD have documented increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) with methylphenidate.<sup>1,2,3,4</sup> These reported changes have generally been highly variable, of relatively modest magnitude (DBP: 1.5 to 4 mm Hg, SBP: 3.3 to 3.5 mm Hg, HR: 3.9 to 5.6 bpm), but statistically significant.<sup>1,2,3,4</sup> Specific data in hypertensive patients being treated with an antihypertensive are lacking.<br><br>Available data suggest that methylphenidate increases blood pressure and heart rate via its central dopaminergic effects and dopamine-induced increases in circulating epinephrine concentrations.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. <i>Biol Psychiatry</i>. 2006;59(9):829-835. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16373066\">[PubMed 16373066]</a></p>\n<p>2. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. <i>Pediatr Nephrol</i>. 2006;21(1):92-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16254730\">[PubMed 16254730]</a></p>\n<p>3. Wilens TE, Biederman J, Lerner M; Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. <i>J Clin Psychopharmacol</i>. 2004;24(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14709945\">[PubMed 14709945]</a></p>\n<p>4. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. <i>J Clin Psychiatry</i>. 2005;66(2):253-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15705013\">[PubMed 15705013]</a></p>\n<p>5. Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. <i>Psychopharmacology (Berl)</i>. 2003;166(3):264-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589522\">[PubMed 12589522]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10022":"<p><b>Title</b> Antihypertensive Agents / Mirabegron</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mirabegron may diminish the antihypertensive effect of Antihypertensive Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The mirabegron prescribing information reports dose-dependent increases in blood pressure with use.<sup>1</sup> In healthy volunteers mirabegron (at doses of up to 50 mg) produced mean maximum increases in systolic/diastolic blood pressure of 3.5/1.5 mm Hg versus placebo. However, in overactive bladder (OAB) patients, including those with pre-existing hypertension, receiving a maximum dose of mirabegron 50 mg, the systolic/diastolic blood pressure was only 0.5 to 1 mm Hg greater than placebo. OAB patients infrequently reported worsening of pre-existing hypertension with mirabegron. Both systolic and diastolic blood pressure increases were reversible with the discontinuation of mirabegron.<br><br>Based on these findings, the mirabegron prescribing information recommends periodic monitoring of blood pressure throughout therapy, particularly in patients with pre-existing hypertension.<sup>1</sup> Caution should also be taken to monitor patients for drug interactions with mirabegron, especially with CYP2D6 substrates, which may alter blood pressure control. Adjustments to mirabegron dosing in patients with renal and/or hepatic impairment should be made to avoid potential increases in blood pressure.<br><br>The specific mechanism for mirabegron increasing blood pressure is uncertain, but mirabegron has been shown to produce beta-1 adrenergic receptor stimulation at a dose of 200 mg, a 4-fold increase above the maximum recommended daily dose.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Myrbetriq (mirabegron) extended-release tablets [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10023":"<p><b>Title</b> Antihypertensive Agents / Yohimbine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Yohimbine may diminish the antihypertensive effect of Antihypertensive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for possible decreased blood pressure-lowering effectiveness of antihypertensive agents when used with yohimbine.</p>\n<div>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Considering the known actions of yohimbine, primarily an alpha-2 antagonist, a potential interaction with antihypertensive agents exists.<sup>1</sup> Though specific data concerning yohimbine and antihypertensive combination therapy are lacking, many studies have evaluated the hemodynamic impact of yohimbine on both healthy volunteers and hypertensive patients. According to a review article summarizing many such studies, yohimbine has been shown to exert a dose-dependent increase in blood pressure, without increasing heart rate.<sup>1</sup> Hypertensive patients appear to be more sensitive to the blood pressure-increasing effects than normotensive individuals.<br><br>As an alpha-2 antagonist, yohimbine increases sympathetic outflow and circulating norepinephrine concentrations, leading to an increase in blood pressure.<sup>1</sup> As a result of these effects, concurrent use of yohimbine with antihypertensive agents would be expected to diminish the blood pressure-lowering effectiveness of such agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. <i>Pharmacol Ther</i>. 2001;91(3):215-243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11744068\">[PubMed 11744068]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10024":"<p><b>Title</b> Blood Pressure Lowering Agents / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor hemodynamic changes, specifically for signs of hypotension, if using barbiturates with blood pressure lowering medications. Sustained or severe hypotension may require pharmacologic intervention.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Anesthetics have been linked to hypotension, and the risk seems to be heightened in the setting of surgical stress and concomitant use of blood pressure-lowering medications, such as angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, regardless of whether such antihypertensive medications are held.<sup>1</sup> Barbiturates, in particular, have been associated with increased risk of clinically significant hypotension; for every four patients treated with barbiturates, one additional patient experienced hypotension among brain injury patients according to a review.<sup>2</sup><br><br>The mechanism by which anesthetics, in general, or barbiturates, more specifically, lower blood pressure is uncertain, but it may be related to the attenuating effect of anesthetics on the sympathetic system and reduction of baroreceptor sensitivity, hindering the physiologic response to hemodynamic changes, which may particularly occur in surgery or trauma. Another potential mechanism is a reduction in circulating catecholamines, as thiopental, among other anesthetics, has been shown to decrease norepinephrine and epinephrine plasma levels.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mets B. Management of hypotension associated with angiotensin-axis blockade and general anesthesia administration. <i>J Cardiothorac Vasc Anesth</i>. 2013;27(1):156-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22854335\">[PubMed 22854335]</a></p>\n<p>2. Roberts I, Sydenham E. Barbiturates for acute traumatic brain injury. <i>Cochrane Database Syst Rev</i>. 2012;12:CD000033. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23235573\">[PubMed 23235573]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10025":"<p><b>Title</b> DULoxetine / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for orthostatic hypotension or syncope. Counsel patients regarding the risk of orthostatic hypotension or syncope, including symptoms and means of minimizing the risk and consequences. Consider discontinuing duloxetine in patients who experience symptomatic orthostatic hypotension or syncope.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The prescribing information for duloxetine states that concurrent use of medications that can lower blood pressure may increase the risk of orthostatic hypotension or syncope and consideration should be given to discontinuing duloxetine if a patient experiences symptoms.<sup>1</sup> Multiple studies report no significant change in supine and standing blood pressure.<sup>2,3,4,5,6</sup> Some studies noted a small but significant change in orthostatic systolic blood pressure (including a study with doses of 120 mg twice daily or greater).<sup>2,6,7</sup> Contrary to these findings, other studies have cited duloxetine treatment to a small increase in blood pressure that would stabilize and have no long term risk for sustained blood pressure elevation (including a study with doses of 120 mg twice daily or greater).<sup>7,8,9,10,11,12,13,14</sup> The change in blood pressure was transient, most common in the first week, and stabilized over time. Additionally, dizziness is noted to be a common adverse effect that may contribute to the interaction.<sup>1,2</sup><br><br>The mechanism of this interaction is currently unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2012.</p>\n<p>2. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. <i>J Clin Psychopharmacol</i>. 2008;28(1):32-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18204338\">[PubMed 18204338]</a></p>\n<p>3. Goldstein DJ. Duloxetine in the treatment of major depressive disorder. <i>Neuropsychiatr Dis Treat</i>. 2007;3(2):193-209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19300553\">[PubMed 19300553]</a></p>\n<p>4. Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. <i>Prim Care Companion J Clin Psychiatry</i>. 2006;8(4):212-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16964316\">[PubMed 16964316]</a></p>\n<p>5. Cowen PJ, Ogilvie AD, Gama J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. <i>Curr Med Res Opin</i>. 2005;21(3):345-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15811202\">[PubMed 15811202]</a></p>\n<p>6. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. <i>J Clin Pharmacol</i>. 2000;40(2):161-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10664922\">[PubMed 10664922]</a></p>\n<p>7. Derby MA, Zhang L, Chappell JC, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. <i>J Cardiovasc Pharmacol</i>. 2007;49(6):384-393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17577103\">[PubMed 17577103]</a></p>\n<p>8. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang Fl. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. <i>Drug Saf</i>. 2007;30(5):437-455. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17472422\">[PubMed 17472422]</a></p>\n<p>9. Prakash A, Lobo E, Kratochvil CJ, et al. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(1):48-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22251023\">[PubMed 22251023]</a></p>\n<p>10. Pangallo BA, Zhang Q, Desaiah D, et al. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. <i>Curr Med Res Opin</i>. 2010;26(11):2643-2651. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20932222\">[PubMed 20932222]</a></p>\n<p>11. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. <i>Curr Med Res Opin</i>. 2007;23(1):175-184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17257478\">[PubMed 17257478]</a></p>\n<p>12. Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. <i>Depress Anxiety</i>. 2007;24(1):41-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16845641\">[PubMed 16845641]</a></p>\n<p>13. Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JMl. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. <i>J Natl Med Assoc</i>. 2006;98(3):437-447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573311\">[PubMed 16573311]</a></p>\n<p>14. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. <i>J Clin Psychiatry</i>. 2003;64(10):1237-1244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14658974\">[PubMed 14658974]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10026":"<p><b>Title</b> Blood Pressure Lowering Agents / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mianserin may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action needed.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> According to the summary of product characteristics for multiple mianserin products, mianserin may enhance the blood pressure-lowering of certain hypotensive drugs even though mianserin itself is not expected to exert a significant hypotensive effect.<sup>1,2,3</sup> Specifically, potentially enhanced hypotensive effects of diazoxide, hydralazine, and nitroprusside are included in this warning, but no specific data are presented to support this warning. It is also noted that mianserin is not expected to alter the effects of clonidine, guanethidine, or propranolol.<sup>1,2,3</sup> Animal studies have similarly reported significantly enhanced hypotensive effects of prazosin with mianserin, but no evidence of an interaction with enalapril or propranolol.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>2. Tolvon (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>3. Lumin (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>4. Gorska D, Andrzejczak D. Interaction of mianserin and some hypotensive drugs in Wistar rats. <i>Acta Pol Pharm</i>. 2004;61(2):151-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15493298\">[PubMed 15493298]</a></p>\n<p>5. Gorska D, Andrzejczak D. Influence of mianserin on the activity of some hypotensive drugs in spontaneously hypertensive rats. <i>Pol J Pharmacol</i>. 2003;55(3):409-417. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14506320\">[PubMed 14506320]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10027":"<p><b>Title</b> Blood Pressure Lowering Agents / Nicorandil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicorandil may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of excessive blood pressure lowering if using nicorandil with a blood pressure lowering agent.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Nicorandil labeling states that nicorandil can lower blood pressure and that concurrent use with other blood pressure lowering medications may result in an excessive blood pressure reduction.<sup>1,2</sup> As described in nicorandil labeling, a study in hypertensive patients showed that single doses of nicorandil (10 mg, 20 mg, and 30 mg) resulted in substantial reductions of both systolic and diastolic blood pressure, with maximal effects at 4 to 6 hours.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ikorel (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>2. Ikorel (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10028":"<p><b>Title</b> Antipsychotic Agents (Second Generation [Atypical]) / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution with concurrent use of second generation (atypical) antipsychotic agents and any blood pressure-lowering medications. Monitor blood pressure closely, especially during antipsychotic initiation or dose titration, and caution patients regarding the potential for orthostatic hypotension and syncope.</p>\n<div>\n <p><b>Antipsychotic Agents (Second Generation [Atypical]) Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Blonanserin, Brexpiprazole, Cariprazine, Clothiapine, CloZAPine, Iloperidone, Lurasidone, OLANZapine, Paliperidone, QUEtiapine, RisperiDONE, Sulpiride, Ziprasidone</p>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Due to the alpha-1 adrenergic blocking activity of second generation (atypical) antipsychotic agents, patients may experience excessive hypotensive effects when taking these antipsychotic agents concomitantly with blood pressure lowering agents. While the incidence of hypotension, orthostatic hypotension, or syncope with the use of second generation antipsychotic agents appears to be fairly low (0.4% to 7%), the concomitant use of blood pressure lowering agents may increase this risk.<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup><br><br>The prescribing information for second generation antipsychotic agents states that orthostatic hypotension and syncope may occur with the use of second generation antipsychotic medications. Increased monitoring for these effects is recommended in patients with known cardiovascular disease, dehydration, or hypovolemia, or those taking blood pressure lowering medications.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Geodon (ziprasidone) [prescribing information]. New York, NY: Pfizer Inc; August 2015.</p>\n<p>2. Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; April 2014.</p>\n<p>3. Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.</p>\n<p>4. Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; April 2014.</p>\n<p>5. Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2015.</p>\n<p>6. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; July 2013.</p>\n<p>7. Fanapt (iloperidone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p>8. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>9. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; July 2015.</p>\n<p>10. Saphris (asenapine) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; March 2015.</p>\n<p>11. Aristada (aripiprazole lauroxil) [prescribing information]. Waltham, MA: Alkermes Inc; October 2015.</p>\n<p>12. Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; December 2014.</p>\n<p>13. Vraylar (cariprazine) [prescribing information]. Parsippany, NJ: Actavis Pharm Inc; September 2015.</p>\n<p>14. Solian (amisulpride) [summary of product characteristics]. Guildford, Surrey, UK: Sanofi-Aventis; October 2014.</p>\n<p>15. Dolmatil (sulpiride) [summary of product characteristics]. Guildford, Surrey, UK: Sanofi-Aventis; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10029":"<p><b>Title</b> Levodopa / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Caution patients about the possible increased risk for symptomatic postural hypotension when using levodopa in combination with any other drugs that can cause a decrease in blood pressure. Advise patients to stand up slowly from sitting or lying positions in order to minimize the risk of dizziness or falls associated with orthostatic hypotension.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Cases of symptomatic postural hypotension have been reported when levodopa is used alone or when added to the treatment of patients receiving antihypertensive drugs.<sup>1,2</sup> In a study of 100 patients being treated with levodopa, 25 patients experienced significant orthostatic hypotension, identified as a drop of systolic blood pressure of 30 mm Hg or a drop in systolic blood pressure to 80 mm Hg or less.<sup>3</sup> Hypotensive events often occurred early during treatment and disappeared without a dose decrease in levodopa. Although not well understood, proposed mechanisms include impaired catecholamine action, abnormalities of rennin and aldosterone action, and negative inotropic mechanisms leading to decreased cardiac output.<sup>4,5</sup><br><br>Due to the potential for additive blood pressure lowering effects, caution should be exercised when levodopa and antihypertensive agents are administered concomitantly. Dosage adjustment of the antihypertensive drug may be required, especially when simultaneous therapy with levodopa is first initiated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sinemet (carbidopa levodopa) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</p>\n<p>2. McDowell F, Lee JE, Swift T, Sweet RD, Ogsbury JS, Kessler JT. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). <i>Ann Intern Med</i>. 1970;72(1):29-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5410397\">[PubMed 5410397]</a></p>\n<p>3. Stumpf JL, Mitrzyk B. Management of orthostatic hypotension. <i>Am J Hosp Pharm</i>. 1994;51(5):648-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8203384\">[PubMed 8203384]</a></p>\n<p>4. Chokroverty S, Barron KD, Katz FH, Del Greco F, Sharp JT. The syndrome of primary orthostatic hypotension. <i>Brain</i>. 1969;92(4):743-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5364007\">[PubMed 5364007]</a></p>\n<p>5. Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2014;20(1):815-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24819390\">[PubMed 24819390]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10030":"<p><b>Title</b> Hypotension-Associated Agents / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Although the concomitant use of two or more drugs that may lower blood pressure (either as a therapeutic intention or as an adverse effect) is often clinically appropriate, use of such combinations often substantially increases the risk for hypotension. Monitor patients closely for additive hypotensive effects if two or more of these agents are combined.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n <p><b>Hypotension-Associated Agents Interacting Members</b> Aldesleukin, Amifostine, Amiodarone, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arsenic Trioxide, Bortezomib, Bretylium, Bromocriptine, Bupivacaine, Carbetocin, ChlorproMAZINE, Clofarabine, ClomiPRAMINE, CloZAPine, Conivaptan, Desflurane, Dexmedetomidine, Dinutuximab, Epoprostenol, Ferric Gluconate, Halothane, Iloprost, Imipramine, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Levobupivacaine, Levodopa, Levosimendan, Lofexidine, Morphine (Liposomal), Morphine (Systemic), Nabilone, Nesiritide, Nitric Oxide, Nitroglycerin, Obinutuzumab, PACLitaxel (Conventional), Pergolide, Phenelzine, Pipamperone [INT], Pramipexole, Promazine, Propofol, Rasagiline, Remifentanil, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Streptokinase, SUFentanil, Tamsulosin, Thalidomide, Thioridazine, TiZANidine, Tolazoline, Tolcapone, Tranylcypromine, Tretinoin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Each drug listed in this monograph is capable of causing clinically significant hypotension (either as a desired effect or as an adverse effect) independent of other drug therapy. These drugs are included because they are used for the treatment of hypertension; have been reported to cause clinically significant hypotension at a frequency of at least 10%; have been reported to cause clinically significant hypotension at a frequency of at least 5% and have label warnings of a possible increased risk for hypotension requiring additional monitoring or concomitant medication dose adjustment; or because published literature suggests a significant risk of hypotension with their use. Although numerous factors affect a patient's risk for hypotension (eg, age, volume status, baseline blood pressure, comorbid disease states, etc) concomitant use of two or more of these drugs may increase their risk.<sup>1,2,3,4,5,6,7,8,9</sup> Increased blood pressure monitoring is advised and dose adjustments may be required.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Apokyn (apomorphine) [prescribing information]. Louisville, KY: US WorldMeds LLC; July 2014.</p>\n<p>2. Velcade (bortezomib) [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc; September 2015.</p>\n<p>3. Cycloset (bromocriptine) [prescribing information]. Tiverton, RI: VeroScience LLC; October 2015.</p>\n<p>4. Marplan (isocarboxazid) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals; June 2007.</p>\n<p>5. Sinemet (carbidopa levodopa) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2014.</p>\n<p>6. Nardil (phenelzine) [prescribing information]. New York, NY: Pfizer Inc; May 2007.</p>\n<p>7. Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2014.</p>\n<p>8. Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013.</p>\n<p>9. Parnate (tranylcypromine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10031":"<p><b>Title</b> Bedaquiline / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Bedaquiline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to this combination. Concomitant use should only occur if the benefit of coadministration outweighs the risk. If combined, monitor for increased bedaquiline effects/toxicities (eg, QTc interval prolongation).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers summarized in product labeling, lopinavir/ritonavir (400 mg/100 mg twice daily for 24 days) increased the bedaquiline (400 mg single dose) AUC by 22%.<sup>1,2</sup> In a clinical study of patients with drug-resistant tuberculosis, 14 patients treated with bedaquiline in combination with lopinavir/ritonavir had an approximately 2-fold greater bedaquiline AUC (after an average of 95 days of treatment) compared with 17 patients receiving bedaquiline without antiretroviral treatment (after an average of 43 days of treatment).<sup>3</sup> Bedaquiline half-life was approximately 24 hours longer, and the time to maximum concentration was 2 hours longer, in patients receiving lopinavir/ritonavir. M2 (bedaquiline active metabolite) exposure was similar between groups. Pharmacokinetic modeling of this clinical study predicted that after 168 days of combined treatment with bedaquiline and lopinavir/ritonavir, the bedaquiline AUC would be increased 2.9-fold.<sup>4</sup><br><br>The suspected primary mechanism of this interaction is lopinavir/ritonavir inhibition of CYP3A4-mediated bedaquiline metabolism. US labeling for bedaquiline and lopinavir/ritonavir encourages a risk/benefit assessment prior to initiating this combination.<sup>1,2</sup> However, the magnitude of interaction between these agents remains poorly-defined. Because bedaquiline has a long terminal half-life of approximately 4 to 5.5 months,<sup>2,5</sup> it is unlikely that either study to date measured even a simple majority of bedaquiline postdose exposure (thus, among other issues, different fractions of the total elimination period were captured in the different groups). Interpretation of the study in tuberculosis-infected patients is further complicated by differences in length of treatment between groups; bedaquilline is expected to continue accumulating after 43 or even 95 days of treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kaletra (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2015.</p>\n<p>2. Sirturo (bedaquiline) [prescribing information]. Titusville, NJ: Janssen Therapeutics; May 2015.</p>\n<p>3. Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. <i>J Antimicrob Chemother</i>. 2016;71(4):1037-1040. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26747099\">[PubMed 26747099]</a></p>\n<p>4. Brill MJ, Svensson EM, Pandie M, Maartens G, Karlsson MO. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavit/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. <i>Int J Antimicrob Agents</i>. 2017;49(2):212-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28038962\">[PubMed 28038962]</a></p>\n<p>5. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. <i>Antimicrob Agents Chemother</i>. 2014;58(11):6406-6412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25114140\">[PubMed 25114140]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10032":"<p><b>Title</b> Deferiprone / Myelosuppressive Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of deferiprone and myelosuppressive agents. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.</p>\n<div>\n <p><b>Myelosuppressive Agents Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Aldesleukin, Alemtuzumab, Altretamine, Amsacrine, Arsenic Trioxide, AzaCITIDine, Belinostat, Belotecan, Bendamustine, Bevacizumab, Bexarotene (Systemic), Blinatumomab, Bortezomib, Bosutinib, Busulfan, Cabazitaxel, Capecitabine, CarBAMazepine, Carbimazole, CARBOplatin, Carfilzomib, Carmustine, Chlorambucil, Chloramphenicol (Ophthalmic), Chloramphenicol (Systemic), CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, Daratumumab, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, Dexrazoxane, Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Edetate CALCIUM Disodium, EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Everolimus, Floxuridine, Flucytosine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Inotuzumab Ozogamicin, Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Ixazomib, Lenalidomide, Linezolid, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, MethIMAzole, Methotrexate, Midostaurin, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Nilotinib, Niraparib, Obinutuzumab, Olaparib, Olaratumab, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Peginterferon Alfa-2a, Peginterferon Alfa-2b, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PONATinib, Procarbazine, Propylthiouracil, Radium Ra 223 Dichloride, Radotinib, Raltitrexed, Ribociclib, RiTUXimab, RomiDEPsin, Rucaparib, Ruxolitinib, Sirolimus, SORAfenib, Streptozocin, Tacrolimus (Systemic), Tedizolid, Tegafur, Temozolomide, Temsirolimus, Teniposide, Thalidomide, Thioguanine, Thiotepa, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Trifluridine and Tipiracil, Venetoclax, VinBLAStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zidovudine, Ziv-Aflibercept (Systemic)</p>\n</div> \n<p><b>Discussion</b> According to deferiprone prescribing information, neutropenia or decreased neutrophil counts occurred in 6% to 7% of deferiprone treated patients and agranulocytosis occurred in 2% of patients.<sup>1,2</sup> Labeling contains a boxed warning stating that neutropenia may precede agranulocytosis and agranulocytosis may lead to serious infection or death.<sup>1,2</sup>The concomitant use of deferiprone and drugs that can lead to neutropenia should be avoided.<sup>1,2</sup> If combination therapy cannot be avoided, absolute neutrophil counts should be monitored more closely than what is recommended for typical deferiprone use (ie, more often than weekly).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ferriprox (deferiprone) tablets. Rockville, MD: ApoPharma USA Inc; February 2015.</p>\n<p>2. Ferriprox (deferiprone) oral solution. Rockville, MD: ApoPharma USA Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10033":"<p><b>Title</b> Apixaban / Antiplatelet Agents (P2Y12 Inhibitors)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. US and Canadian apixaban labeling recommend caution and increased monitoring if used with any antiplatelet agent. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.</p>\n<div>\n <p><b>Antiplatelet Agents (P2Y12 Inhibitors) Interacting Members</b> Cangrelor, Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine</p>\n</div> \n<p><b>Discussion</b> Concomitant use of aspirin with apixaban has been shown to increase bleeding risk from 1.8% per year to 3.4% per year in patients with atrial fibrillation.<sup>1,2</sup> Apixaban combined with aspirin and/or clopidogrel was associated with an increased risk of major bleeding (1.3% versus 0.5%) for post-acute coronary syndrome (ACS) high-risk patients in a randomized control trial that was terminated early due to bleeding events.<sup>3</sup> In a phase 2 trial, doses above the approved maximum dose (10 mg/day) were associated with an increased risk of bleeding whereas therapeutic doses (i.e., 10 mg/day or less) showed only a non-significant increase in bleeding events.<sup>4</sup> Patients using dual antiplatelet therapy (clopidogrel and aspirin) together with apixaban had more bleeding events in the study. The use of these medications concomitantly is not contraindicated unless there is active bleeding,<sup>1</sup> but clinical benefit and risk should be assessed for each patient. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2015.</p>\n<p>2. Granger CB, Alexander JH, McMurrary JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOLE). <i>N Engl J Med</i>. 2011;365:981-992. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21870978\">[PubMed 21870978]</a></p>\n<p>3. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. <i>N Engl J Med</i>. 2011;365(8):699-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21780946\">[PubMed 21780946]</a></p>\n<p>4. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after actue coronary syndrome. <i>Circulation</i>. 2009;119(22):2877-2885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19470889\">[PubMed 19470889]</a></p>\n<p>5. Eliquis (apixaban) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10034":"<p><b>Title</b> Apixaban / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. US and Canadian apixaban labeling recommend caution and increased monitoring if used with any antiplatelet agent. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.</p> \n<p><b>Discussion</b> Concomitant use of aspirin with apixaban has been shown to increase bleeding risk from 1.8% per year to 3.4% per year in patients with atrial fibrillation.<sup>1,2</sup> Apixaban combined with aspirin and/or clopidogrel was associated with an increased risk of major bleeding (1.3% versus 0.5%) for post-acute coronary syndrome (ACS) high-risk patients in a randomized control trial that was terminated early due to bleeding events.<sup>3</sup> In a phase 2 trial, doses above the approved maximum dose (10 mg/day) were associated with an increased risk of bleeding whereas therapeutic doses (i.e., 10 mg/day or less) showed only a non-significant increase in bleeding events.<sup>4</sup> Patients using dual antiplatelet therapy (clopidogrel and aspirin) together with apixaban had more bleeding events in the study. The use of these medications concomitantly is not contraindicated unless there is active bleeding,<sup>1</sup> but clinical benefit and risk should be assessed for each patient. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2015.</p>\n<p>2. Granger CB, Alexander JH, McMurrary JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOLE). <i>N Engl J Med</i>. 2011;365:981-992. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21870978\">[PubMed 21870978]</a></p>\n<p>3. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. <i>N Engl J Med</i>. 2011;365(8):699-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21780946\">[PubMed 21780946]</a></p>\n<p>4. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after actue coronary syndrome. <i>Circulation</i>. 2009;119(22):2877-2885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19470889\">[PubMed 19470889]</a></p>\n<p>5. Eliquis (apixaban) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10035":"<p><b>Title</b> Apixaban / Nonsteroidal Anti-Inflammatory Agents (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). The risks likely vary according to the NSAID dose and anticipated duration of use. If combined, monitor patients extra closely for signs and symptoms of bleeding with any concurrent use, and counsel patients about the increased risk of bleeding and the need to promptly report any signs or symptoms of possible bleeding. UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Concomitant use of aspirin with apixaban has been shown to increase bleeding risk from 1.8% per year to 3.4% per year in patients with atrial fibrillation.<sup>1,2</sup> Apixaban combined with aspirin and/or clopidogrel was associated with an increased risk of major bleeding (1.3% versus 0.5%) for post-acute coronary syndrome (ACS) high-risk patients in a randomized control trial that was terminated early due to bleeding events.<sup>3</sup> In a phase 2 trial, doses above the approved maximum dose (10 mg/day) were associated with an increased risk of bleeding whereas therapeutic doses (i.e., 10 mg/day or less) showed only a non-significant increase in bleeding events.<sup>4</sup> Patients using dual antiplatelet therapy (clopidogrel and aspirin) together with apixaban had more bleeding events in the study. The use of these medications concomitantly is not contraindicated unless there is active bleeding,<sup>1</sup> but clinical benefit and risk should be assessed for each patient. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2015.</p>\n<p>2. Granger CB, Alexander JH, McMurrary JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOLE). <i>N Engl J Med</i>. 2011;365:981-992. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21870978\">[PubMed 21870978]</a></p>\n<p>3. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. <i>N Engl J Med</i>. 2011;365(8):699-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21780946\">[PubMed 21780946]</a></p>\n<p>4. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after actue coronary syndrome. <i>Circulation</i>. 2009;119(22):2877-2885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19470889\">[PubMed 19470889]</a></p>\n<p>5. Eliquis (apixaban) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10036":"<p><b>Title</b> Dabigatran Etexilate / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. Increase monitoring for evidence of bleeding if dabigatran is used in combination with any antiplatelet agent. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use of prasugrel or ticagrelor, and it additionally recommends that low dose (100 mg/day) aspirin could be considered if necessary but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.</p> \n<p><b>Discussion</b> The use of dabigatran in combination with any antiplatelet agent is expected to increase the risk of bleeding. In patients with atrial fibrillation treated with aspirin or clopidogrel for prevention of stroke and systemic embolism, the risk of major bleeding with dabigatran was approximately doubled, without any apparent benefit in reducing embolic risk.<sup>1</sup> The dabigatran Canadian product monograph recommends avoiding concomitant use of dabigatran with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>1</sup> It additionally recommends that low dose (100 mg/day) aspirin could be considered if medically necessary, but should not be used for stroke prevention in patients with atrial fibrillation. U.S. prescribing information for dabigatran does not recommend any specific antiplatelet agents that should be avoided, or additional action that should be taken to limit bleeding risk with these combinations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pradaxa (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; June 2015.</p>\n<p>2. Pradaxa (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10037":"<p><b>Title</b> Dabigatran Etexilate / Antiplatelet Agents (P2Y12 Inhibitors)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. Increase monitoring for evidence of bleeding if dabigatran is used in combination with any antiplatelet agent. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use of prasugrel or ticagrelor, and it additionally recommends that low dose (100 mg/day) aspirin could be considered if necessary but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.</p>\n<div>\n <p><b>Antiplatelet Agents (P2Y12 Inhibitors) Interacting Members</b> Cangrelor, Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine</p>\n</div> \n<p><b>Discussion</b> The use of dabigatran in combination with any antiplatelet agent is expected to increase the risk of bleeding. In patients with atrial fibrillation treated with aspirin or clopidogrel for prevention of stroke and systemic embolism, the risk of major bleeding with dabigatran was approximately doubled, without any apparent benefit in reducing embolic risk.<sup>1</sup> The dabigatran Canadian product monograph recommends avoiding concomitant use of dabigatran with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>1</sup> It additionally recommends that low dose (100 mg/day) aspirin could be considered if medically necessary, but should not be used for stroke prevention in patients with atrial fibrillation. U.S. prescribing information for dabigatran does not recommend any specific antiplatelet agents that should be avoided, or additional action that should be taken to limit bleeding risk with these combinations.<sup>2</sup><br><br>In addition to the expected pharmacodynamic interaction between dabigatran and antiplatelet agents, clopidogrel specifically increased dabigatran maximum concentration and AUC by 30% and 40%, respectively.<sup>1</sup> The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pradaxa (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; June 2015.</p>\n<p>2. Pradaxa (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10038":"<p><b>Title</b> Dabigatran Etexilate / Nonsteroidal Anti-Inflammatory Agents (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). The risks likely vary according to the NSAID dose and anticipated duration of use. If combined, monitor patients extra closely for signs and symptoms of bleeding with any concurrent use, and counsel patients about the increased risk of bleeding and the need to promptly report any signs or symptoms of possible bleeding. UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The use of dabigatran in combination with any antiplatelet agent, including NSAIDs, is expected to increase the risk of bleeding. In patients with atrial fibrillation treated with aspirin or clopidogrel for prevention of stroke and systemic embolism, the risk of major bleeding with dabigatran was approximately doubled, without any apparent benefit in reducing embolic risk.<sup>1</sup> The dabigatran Canadian product monograph recommends avoiding concomitant use of dabigatran with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>1</sup> It additionally recommends that low dose (100 mg/day) aspirin could be considered if medically necessary, but should not be used for stroke prevention in patients with atrial fibrillation. U.S. prescribing information for dabigatran does not recommend any specific antiplatelet agents that should be avoided, or additional action that should be taken to limit bleeding risk with these combinations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pradaxa (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; June 2015.</p>\n<p>2. Pradaxa (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10039":"<p><b>Title</b> Rivaroxaban / Antiplatelet Agents (P2Y12 Inhibitors)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. US and Canadian rivaroxaban labeling recommend caution and increased monitoring if used with any antiplatelet agent. Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended. Any combined use should only be undertaken with increased monitoring for evidence of bleeding.</p>\n<div>\n <p><b>Antiplatelet Agents (P2Y12 Inhibitors) Interacting Members</b> Cangrelor, Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine</p>\n</div> \n<p><b>Discussion</b> When added to patients with acute coronary syndrome who were taking aspirin alone or aspirin plus a thienopyridine, rivaroxaban use was associated with a dose-dependent increase in the risk for bleeding (hazard ratio [HR] = 2.2 to 5.1 for doses from 5 mg to 20 mg/day) compared to placebo (n=3491).<sup>1</sup> In an analysis combining trials for the use of rivaroxaban for the treatment of venous thromboembolism, clinically relevant major bleeding increased with nonsteroidal anti-inflammatory drug (NSAID) use (HR, 1.90 [95% CI, 1.45-2.49]) and aspirin use (HR, 1.81 [95% CI, 1.36-2.42) compared with rivaroxaban alone.<sup>2</sup>. Product labeling also lists aspirin use as an independent risk factor for bleeding and concurrent use of rivaroxaban (15 mg/day) with clopidogrel (300 mg loading dose, then 75 mg/day) was associated with an approximate doubling of bleeding time in 30%-45% of patients in 2 separate studies.<sup>3,4</sup> In contrast, a study in healthy volunteers concluded that there were no pharmacokinetic or pharmacodynamic interactions between aspirin and rivaroxaban.<sup>5</sup><br><br>Rivaroxaban labeling cautions that concomitant aspirin use has been identified as an independent risk factor for major bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Caution and increased monitoring for bleeding should be exercised if rivaroxaban is combined with any antiplatelet agent.<sup>2</sup> The rivaroxaban Canadian product monograph recommends avoiding concomitant use of rivaroxaban with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet</i>. 2009;374(9683):29-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19539361\">[PubMed 19539361]</a></p>\n<p>2. Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin [published online April 14, 2014]. <i>JAMA Intern Med</i>. doi: 10.1001/jamainternmed.2014.946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24733305\">[PubMed 24733305]</a></p>\n<p>3. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2015.</p>\n<p>4. Xarelto (rivaroxaban) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc.; May 2015.</p>\n<p>5. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. <i>J Clin Pharmacol</i>. 2006;46(9):981-990. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920892\">[PubMed 16920892]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10040":"<p><b>Title</b> Rivaroxaban / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. US and Canadian rivaroxaban labeling recommend caution and increased monitoring if used with any antiplatelet agent. Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended. Any combined use should only be undertaken with increased monitoring for evidence of bleeding.</p> \n<p><b>Discussion</b> When added to patients with acute coronary syndrome who were taking aspirin alone or aspirin plus a thienopyridine, rivaroxaban use was associated with a dose-dependent increase in the risk for bleeding (hazard ratio [HR] = 2.2 to 5.1 for doses from 5 mg to 20 mg/day) compared to placebo (n=3491).<sup>1</sup> In an analysis combining trials for the use of rivaroxaban for the treatment of venous thromboembolism, clinically relevant major bleeding increased with nonsteroidal anti-inflammatory drug (NSAID) use (HR, 1.90 [95% CI, 1.45-2.49]) and aspirin use (HR, 1.81 [95% CI, 1.36-2.42) compared with rivaroxaban alone.<sup>2</sup>. Product labeling also lists aspirin use as an independent risk factor for bleeding and concurrent use of rivaroxaban (15 mg/day) with clopidogrel (300 mg loading dose, then 75 mg/day) was associated with an approximate doubling of bleeding time in 30%-45% of patients in 2 separate studies.<sup>3,4</sup> In contrast, a study in healthy volunteers concluded that there were no pharmacokinetic or pharmacodynamic interactions between aspirin and rivaroxaban.<sup>5</sup><br><br>Rivaroxaban labeling cautions that concomitant aspirin use has been identified as an independent risk factor for major bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Caution and increased monitoring for bleeding should be exercised if rivaroxaban is combined with any antiplatelet agent.<sup>2</sup> The rivaroxaban Canadian product monograph recommends avoiding concomitant use of rivaroxaban with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet</i>. 2009;374(9683):29-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19539361\">[PubMed 19539361]</a></p>\n<p>2. Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin [published online April 14, 2014]. <i>JAMA Intern Med</i>. doi: 10.1001/jamainternmed.2014.946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24733305\">[PubMed 24733305]</a></p>\n<p>3. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2015.</p>\n<p>4. Xarelto (rivaroxaban) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc.; May 2015.</p>\n<p>5. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. <i>J Clin Pharmacol</i>. 2006;46(9):981-990. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920892\">[PubMed 16920892]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10041":"<p><b>Title</b> Rivaroxaban / Nonsteroidal Anti-Inflammatory Agents (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). The risks likely vary according to the NSAID dose and anticipated duration of use. If combined, monitor patients extra closely for signs and symptoms of bleeding with any concurrent use, and counsel patients about the increased risk of bleeding and the need to promptly report any signs or symptoms of possible bleeding. UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> When added to patients with acute coronary syndrome who were taking aspirin alone or aspirin plus a thienopyridine, rivaroxaban use was associated with a dose-dependent increase in the risk for bleeding (hazard ratio [HR] = 2.2 to 5.1 for doses from 5 mg to 20 mg/day) compared to placebo (n=3491).<sup>1</sup> In an analysis combining trials for the use of rivaroxaban for the treatment of venous thromboembolism, clinically relevant major bleeding increased with nonsteroidal anti-inflammatory drug (NSAID) use (HR, 1.90 [95% CI, 1.45-2.49]) and aspirin use (HR, 1.81 [95% CI, 1.36-2.42) compared with rivaroxaban alone.<sup>2</sup>. Product labeling also lists aspirin use as an independent risk factor for bleeding and concurrent use of rivaroxaban (15 mg/day) with clopidogrel (300 mg loading dose, then 75 mg/day) was associated with an approximate doubling of bleeding time in 30%-45% of patients in 2 separate studies.<sup>3,4</sup> In contrast, a study in healthy volunteers concluded that there were no pharmacokinetic or pharmacodynamic interactions between aspirin and rivaroxaban.<sup>5</sup><br><br>Rivaroxaban labeling cautions that concomitant aspirin use has been identified as an independent risk factor for major bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Caution and increased monitoring for bleeding should be exercised if rivaroxaban is combined with any antiplatelet agent.<sup>2</sup> The rivaroxaban Canadian product monograph recommends avoiding concomitant use of rivaroxaban with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet</i>. 2009;374(9683):29-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19539361\">[PubMed 19539361]</a></p>\n<p>2. Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin [published online April 14, 2014]. <i>JAMA Intern Med</i>. doi: 10.1001/jamainternmed.2014.946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24733305\">[PubMed 24733305]</a></p>\n<p>3. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2015.</p>\n<p>4. Xarelto (rivaroxaban) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc.; May 2015.</p>\n<p>5. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. <i>J Clin Pharmacol</i>. 2006;46(9):981-990. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920892\">[PubMed 16920892]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10042":"<p><b>Title</b> Edoxaban / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.</p> \n<p><b>Discussion</b> In clinical studies with edoxaban, concomitant use of aspirin (maximum of 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of clinically relevant bleeding.<sup>1</sup> In studies of healthy volunteers, bleeding times were assessed with the combination of edoxaban (60 mg daily) and low-dose aspirin (100 mg daily), high-dose aspirin (325 mg daily), or naproxen (500 mg daily).<sup>2</sup> Edoxaban and each antiplatelet agent increased bleeding time when administered alone, and combination therapy resulted in an additive effect that prolonged the bleeding time greater than either agent administered alone.<sup>2</sup> Additionally, high-dose aspirin increased the edoxaban AUC and maximum serum concentration 30% and 34%, respectively.<sup>2</sup><br><br>Carefully monitor patients who require treatment with antiplatelet therapy during edoxaban use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; September 2015.</p>\n<p>2. Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodyamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. <i>J Cardiovasc Pharmacol</i>. 2013;62(2):212-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23615159\">[PubMed 23615159]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10043":"<p><b>Title</b> Edoxaban / Agents with Antiplatelet Properties</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> In clinical studies with edoxaban, concomitant use of aspirin (maximum of 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of clinically relevant bleeding.<sup>1</sup> In studies of healthy volunteers, bleeding times were assessed with the combination of edoxaban (60 mg daily) and low-dose aspirin (100 mg daily), high-dose aspirin (325 mg daily), or naproxen (500 mg daily).<sup>2</sup> Edoxaban and each antiplatelet agent increased bleeding time when administered alone, and combination therapy resulted in an additive effect that prolonged the bleeding time greater than either agent administered alone.<sup>2</sup> Additionally, high-dose aspirin increased the edoxaban AUC and maximum serum concentration 30% and 34%, respectively.<sup>2</sup><br><br>Carefully monitor patients who require treatment with antiplatelet therapy during edoxaban use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; September 2015.</p>\n<p>2. Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodyamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. <i>J Cardiovasc Pharmacol</i>. 2013;62(2):212-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23615159\">[PubMed 23615159]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10044":"<p><b>Title</b> Edoxaban / Antiplatelet Agents (P2Y12 Inhibitors)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.</p>\n<div>\n <p><b>Antiplatelet Agents (P2Y12 Inhibitors) Interacting Members</b> Cangrelor, Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine</p>\n</div> \n<p><b>Discussion</b> In clinical studies with edoxaban, concomitant use of aspirin (maximum of 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of clinically relevant bleeding.<sup>1</sup> In studies of healthy volunteers, bleeding times were assessed with the combination of edoxaban (60 mg daily) and low-dose aspirin (100 mg daily), high-dose aspirin (325 mg daily), or naproxen (500 mg daily).<sup>2</sup> Edoxaban and each antiplatelet agent increased bleeding time when administered alone, and combination therapy resulted in an additive effect that prolonged the bleeding time greater than that of either agent alone.<sup>2</sup> Additionally, high-dose aspirin increased the edoxaban AUC and maximum serum concentration 30% and 34%, respectively.<sup>2</sup><br><br>Carefully monitor patients who require treatment with antiplatelet therapy during edoxaban use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; September 2015.</p>\n<p>2. Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodyamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. <i>J Cardiovasc Pharmacol</i>. 2013;62(2):212-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23615159\">[PubMed 23615159]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10045":"<p><b>Title</b> Edoxaban / Nonsteroidal Anti-Inflammatory Agents (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). The risks likely vary according to the NSAID dose and anticipated duration of use. If combined, monitor patients extra closely for signs and symptoms of bleeding with any concurrent use, and counsel patients about the increased risk of bleeding and the need to promptly report any signs or symptoms of possible bleeding. UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> In clinical studies with edoxaban, concomitant use of aspirin (maximum of 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of clinically relevant bleeding.<sup>1</sup> In studies of healthy volunteers, bleeding times were assessed with the combination of edoxaban (60 mg daily) and low-dose aspirin (100 mg daily), high-dose aspirin (325 mg daily), or naproxen (500 mg daily).<sup>2</sup> Edoxaban and each antiplatelet agent increased bleeding time when administered alone, and combination therapy resulted in an additive effect that prolonged the bleeding time greater than that of either agent alone.<sup>2</sup> Additionally, high-dose aspirin increased the edoxaban AUC and maximum serum concentration 30% and 34%, respectively.<sup>2</sup><br><br>Carefully monitor patients who require treatment with antiplatelet therapy during edoxaban use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; September 2015.</p>\n<p>2. Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodyamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. <i>J Cardiovasc Pharmacol</i>. 2013;62(2):212-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23615159\">[PubMed 23615159]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10046":"<p><b>Title</b> Alitretinoin (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 16 healthy volunteers, ketoconazole (200 mg single dose) increased the alitretinoin (30 mg daily for 12 days) AUC and maximum serum concentration 40% and 60%, respectively.<sup>1</sup><br><br>Product labeling for alitretinoin states that coadministration with strong CYP3A4 inhibitors, such as ketoconazole, increases levels of alitretinoin, and dose reduction of alitretinoin should be considered with use of such a combination.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schmitt-Hoffmann AH, Roos B, Sauer J, et al. Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A. <i>Clin Exp Dermatol</i>. 2011;36(suppl 2):24-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21443601\">[PubMed 21443601]</a></p>\n<p>2. Toctino (alitretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10047":"<p><b>Title</b> Atazanavir / Dapsone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapsone (Systemic) may enhance the adverse/toxic effect of Atazanavir. Specifically, the risk of hyperbilirubinemia may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hemolytic anemia and hyperbilirubinemia when dapsone and atazanavir are combined.</p> \n<p><b>Discussion</b> One report describes 2 patients who experienced hemolytic anemia leading to unconjugated hyperbilirubinemia after initiating therapy with atazanavir and dapsone.<sup>1</sup> In both cases, hemolysis subsided and bilirubin levels returned to normal with dapsone discontinuation.<sup>1</sup><br><br>The mechanism of this interaction is unknown. Atazanavir inhibition of CYP3A4, leading to increased dapsone concentrations, may play a role. Additionally, since both atazanavir and dapsone can cause hyperbilirubinemia, their combined effects may be additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. East J, Blanton LS. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. <i>Antimicrob Agents Chemother</i>. 2012;56(2):1081-1083. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22123706\">[PubMed 22123706]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10051":"<p><b>Title</b> Zolpidem / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Zolpidem. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using a lower starting dose of zolpidem in patients receiving ketoconazole and monitor for increased zolpidem effects/toxicities if these agents are combined.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, the zolpidem (5 mg single dose) AUC and maximum serum concentration increased 67% and 35%, respectively, when administered following a 2 day course of ketoconazole (200 mg twice daily).<sup>1,2</sup> Pharmacodynamic changes coinciding with increased serum concentrations were reported (eg, sedation).<sup>1,2</sup><br><br>Zolpidem prescribing information states that consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together.<sup>2</sup><br><br>The mechanism of this interaction is likely due to ketoconazole inhibition of CYP3A4, an enzyme partially responsible for zolpidem metabolism. Inhibition of other routes of zolpidem metabolism or transport by ketoconazole is also likely to play a role since much smaller changes in zolpidem exposure have been seen when combined with other strong CYP3A4 inhibitors (eg, clarithromycin, ritonavir, voriconazole, itraconazole).<sup>1,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. <i>Clin Pharmacol Ther</i>. 1998;64(6):661-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871431\">[PubMed 9871431]</a></p>\n<p>2. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p>3. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. <i>Br J Clin Pharmacol</i>. 2007;63(1):116-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16822278\">[PubMed 16822278]</a></p>\n<p>4. Luurila H, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. <i>Eur J Clin Pharmacol</i>. 1998;54(2):163-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9626922\">[PubMed 9626922]</a></p>\n<p>5. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. <i>J Acquir Immune Defic Syndr</i>. 2000;24(2):129-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10935688\">[PubMed 10935688]</a></p>\n<p>6. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. <i>Clin Pharmacol Ther</i>. 2009;85(6):644-650. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19242403\">[PubMed 19242403]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10052":"<p><b>Title</b> Zolpidem / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased zolpidem effects/toxicities if combined with ritonavir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, ritonavir (200 mg twice daily x 2 days) increased the zolpidem (5 mg single dose) AUC and maximum serum concentration 28% and 22%, respectively.<sup>1</sup> No pharmacodynamic changes related to zolpidem effects were observed.<sup>1</sup><br><br>Zolpidem prescribing information states that concomitant use of strong CYP3A4 inhibitors (ie, ritonavir) may increase zolpidem exposure and effects.<sup>2</sup> Monitor for increased zolpidem toxicities and consider using a lower zolpidem dose if these agents are combined.<sup>2</sup><br><br>The mechanism of this interaction is likely ritonavir mediated inhibition of CYP3A4, an enzyme partially responsible for zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. <i>J Acquir Immune Defic Syndr</i>. 2000;24(2):129-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10935688\">[PubMed 10935688]</a></p>\n<p>2. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC, August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10053":"<p><b>Title</b> Vinorelbine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinorelbine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased vinorelbine effects/toxicities if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a retrospective analysis of 25 patients who received 59 courses of vinorelbine therapy, the incidence of grade 3 or 4 neutropenia was higher in patients who received concomitant therapy with the strong CYP3A4 inhibitor clarithromycin compared with the incidence in patients who did not receive clarithromycin (63.2% vs 27.5%).<sup>1</sup> Due to the small number of patients, other risk factors for neutropenia were not adjusted for in this analysis, and patients who received clarithromycin were older and received higher doses of vinorelbine.<sup>1</sup> One case report describes an itraconazole-treated patient who died 12 days after receiving his first dose of vinorelbine.<sup>2</sup> Various and worsening vinorelbine-associated adverse effects (eg, constipation, mucositis, emesis, granulocytopenia, hypoxia, general deterioration) were noted as soon as 3 days after initial dose administration.<sup>2</sup><br><br>Vinorelbine prescribing information states that concurrent administration of vinorelbine with a CYP3A4 inhibitor may cause an earlier onset and/or an increased severity of adverse reactions.<sup>3</sup><br><br>The mechanism of this potential interaction has not been fully investigated. Vinorelbine is metabolized by CYP3A4, and inhibition of CYP3A4 by clarithromycin, itraconazole, or other strong CYP3A4 inhibitors may play a role. However, in a dedicated pharmacokinetic study, the moderate CYP3A4 inhibitor aprepitant had no effect on the pharmacokinetic parameters of vinorelbine,<sup>4</sup> making the role of CYP3A4 inhibition as the sole mechanism of this interaction uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yano R, Tani D, Watanabe K, et al. Evaluation of potential interaction between vinorelbine and clarithromycin. <i>Ann Pharmacother</i>. 2009;43(3):453-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19261952\">[PubMed 19261952]</a></p>\n<p>2. Bosque E. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. <i>Ann Intern Med</i>. 2001;134(5):427. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11242511\">[PubMed 11242511]</a></p>\n<p>3. Navelbine (vinorelbine) [prescribing information]. Parsippany, NJ: Pierre Fabre Pharmaceuticals Inc; March 2014.</p>\n<p>4. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. <i>Cancer Chemother Pharmacol</i>. 2007;59(3):407-412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17051369\">[PubMed 17051369]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10054":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Sugammadex</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sugammadex may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Sugammadex US and international product labeling states that it may decrease the effectiveness of hormonal contraceptives.<sup>1,2,3,4</sup> Binding studies suggest that sugammadex may bind to progestogen, and receiving sugammadex on the same day as an oral progestin- and/or estrogen-containing contraceptive should be viewed as equivalent to missing contraceptive doses on those days.<sup>1</sup> The use of sugammadex at a 4 mg/kg dose is expected to decrease progestin exposure by an average of 34%.<sup>2,3,4</sup><br><br>The suspected primary mechanism of interaction between these agents is sugammadex binding to progestins, decreasing free and/or total progestin exposure.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bridion (sugammadex) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2015. </p>\n<p>2. Bridion (sugammadex) [summary of product characteristics]. Oss, The Netherlands: NV Organon; July 2013.</p>\n<p>3. Bridion (sugammadex) [Singapore summary of product characteristics]. Whitehouse Station, NJ: Merck &amp; Co Inc; May 2013.</p>\n<p>4. Bridion (sugammadex) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10055":"<p><b>Title</b> Propiverine / MethIMAzole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors): The anticipated significance of this interaction is greater in patients also receiving strong or moderate CYP3A4 inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> MethIMAzole may increase the serum concentration of Propiverine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is normally required when this combination is used. Start at the lowest recommended propiverine dose in patients receiving both methimazole and a strong inhibitor of CYP3A4, and monitor patients receiving these combinations for evidence of propiverine toxicity.</p> \n<p><b>Discussion</b> Propiverine product labeling states that it should be started at the lowest recommended dose in patients receiving methimazole and a strong inhibitor of CYP3A4.<sup>1,2,3</sup> The suspected mechanism of this interaction is inhibition of propiverine metabolism via flavin-containing monooxygenases (by methimazole) and CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Detrunorm (propiverine) tablets [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; August 2014.</p>\n<p>2. Detrunorm XL (propiverine) modified-release capsules [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; June 2014.</p>\n<p>3. Mictoryl (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10056":"<p><b>Title</b> Selexipag / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Strong) may increase the serum concentration of Selexipag. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of selexipag with strong inhibitors of CYP2C8. Concomitant use is listed as a contraindication in selexipag prescribing information.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 20 healthy volunteers, gemfibrozil (600 mg twice daily on days 1 to 9) increased the selexipag (400 mcg single dose given on day 4) AUC and maximum serum concentration (Cmax) 2-fold and 1.4-fold, respectively.<sup>1</sup> The AUC and Cmax of the active metabolite ACT-333679 increased 11.1-fold and 3.6-fold in the presence of gemfibrozil.<sup>1</sup> Adverse events (eg, headache, nausea, vomiting) occurred more frequently with the combination of gemfibrozil and selexipag than with either drug alone.<sup>1</sup><br><br>Selexipag prescribing information states that because exposure to ACT-333679 and selexipag is increased when coadministered with gemfibrozil, use of selexipag with strong CYP2C8 inhibitors is contraindicated.<sup>2</sup><br><br>The suspected mechanism of this interaction is gemfibrozil-mediated inhibition of CYP2C8, an enzyme responsible for the metabolism of ACT333679.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruderer S, Petersen-Sylla M, Boehler M, Remenova T, Halabi A, Dingemanse J. Effect of gemfibrozil or rifampin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects [published online July 17, 2017]. <i>Br J Clin Pharmacol</i>. doi: 10.1111/bcp.13379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28715853\">[PubMed 28715853]</a> </p>\n<p>2. Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceutical US Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10057":"<p><b>Title</b> Selexipag / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Selexipag. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The selexipag AUC was an average of 2.2-fold higher with concurrent lopinavir/ritonavir in a study of 20 healthy volunteers who received a single dose of selexipag 400 mcg with lopinavir/ritonavir 400 mg/100 mg twice daily.<sup>1</sup> Despite this pharmacokinetic change, this interaction is likely of little clinical significance as the AUC of the active ACT-333679 metabolite was only increased by an average of 8% with the combination, and the active metabolite is more than 30-fold more potent and is present in 3- to 4-fold higher concentrations than the parent at steady-state, suggesting it is more significant than the parent selexipag.<sup>1,2</sup><br><br>According to the authors of this study, these findings suggest that no selexipag dose adjustment is required with inhibitors of OATP1B1, OATP1B3, P-glycoprotein, and/or CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. <i>Br J Clin Pharmacol</i>. 2015;80(4):670-677. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25851691\">[PubMed 25851691]</a></p>\n<p>2. Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceutical US, Inc.; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10058":"<p><b>Title</b> Selexipag / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Selexipag. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The selexipag AUC was an average of 2.2-fold higher with concurrent lopinavir/ritonavir in a study of 20 healthy volunteers who received a single dose of selexipag 400 mcg with lopinavir/ritonavir 400 mg/100 mg twice daily.<sup>1</sup> Despite this pharmacokinetic change, this interaction is likely of little clinical significance as the AUC of the active ACT-333679 metabolite was only increased by an average of 8% with the combination, and the active metabolite is more than 30-fold more potent and is present in 3- to 4-fold higher concentrations than the parent at steady-state, suggesting it is more significant than the parent selexipag.<sup>1,2</sup><br><br>According to the authors of this study, these findings suggest that no selexipag dose adjustment is required with inhibitors of OATP1B1, OATP1B3, P-glycoprotein, and/or CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. <i>Br J Clin Pharmacol</i>. 2015;80(4):670-677. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25851691\">[PubMed 25851691]</a></p>\n<p>2. Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceutical US, Inc.; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10059":"<p><b>Title</b> Lesinurad / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Lesinurad. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Lesinurad should not be administered with epoxide hydrolase inhibitors such as valproic acid and its derivatives.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Although specific data regarding this potential interaction are not available, the lesinurad prescribing information cautions to avoid concurrent use with inhibitors of epoxide hydrolase, such as valproic acid and derivatives.<sup>1</sup> According to the prescribing information, epoxide hydrolase is thought to participate in the metabolism of an oxide metabolite of lesinurad.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10060":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Lesinurad</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lesinurad may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of an additional, nonhormonal contraceptive is recommended in patients being treated with lesinurad who desire effective contraception.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Although specific data regarding this potential interaction are not available, the lesinurad prescribing information cautions that an additional, nonhormonal contraceptive is recommended.<sup>1</sup><br><br>The likely reason for this recommendation is that lesinurad is a weak inducer of CYP3A4, which is responsible for the metabolism of most hormonal contraceptives.<sup>1</sup> As a result, lesinurad could decrease concentrations of the hormonal contraceptive, possibly reducing its effectiveness. Use of lesinurad with the CYP3A4 substrates sildenafil and amlodipine was associated with more than a 30% reduction in AUC of the CYP3A4 substrates on average.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10061":"<p><b>Title</b> Progestins (Contraceptive) / Lesinurad</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lesinurad may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of an additional, nonhormonal contraceptive is recommended in patients being treated with lesinurad who desire effective contraception.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Although specific data regarding this potential interaction are not available, the lesinurad prescribing information cautions that an additional, nonhormonal contraceptive is recommended.<sup>1</sup><br><br>The likely reason for this recommendation is that lesinurad is a weak inducer of CYP3A4, which is responsible for the metabolism of most hormonal contraceptives.<sup>1</sup> As a result, lesinurad could decrease concentrations of the hormonal contraceptive, possibly reducing its effectiveness. Use of lesinurad with the CYP3A4 substrates sildenafil and amlodipine was associated with more than a 30% reduction in AUC of the CYP3A4 substrates on average.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10062":"<p><b>Title</b> Lesinurad / Aspirin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is likely only of clinical significance at aspirin doses of greater than 325 mg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aspirin may diminish the therapeutic effect of Lesinurad. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Aspirin at doses of 325 mg/day or less is not expected to interact with lesinurad significantly, but higher doses of aspirin (i.e., more than 325 mg/day) may impair the effectiveness of lesinurad given with allopurinol. If such use with higher doses of aspirin is necessary, monitor the patient closely for evidence of reduced response to lesinurad.</p> \n<p><b>Discussion</b> According to the lesinurad prescribing information, higher doses of aspirin (i.e., more than 325 mg/day) may impair the effectiveness of lesinurad given with allopurinol, but lower aspirin doses are not likely to alter lesinurad effectiveness.<sup>1</sup><br><br>The specific mechanism for this potential interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10072":"<p><b>Title</b> Saquinavir / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Saquinavir. However, the magnitude of this change is unclear, and dosing recommendations for this combination are not available. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of cobicistat with saquinavir or any ritonavir-boosted protease inhibitor is not recommended.</p> \n<p><b>Discussion</b> The labeling for both saquinavir and cobicistat state that concurrent use of cobicistat with saquinavir is not recommended due to a lack of dosing recommendations.<sup>1,2</sup> Further, use of cobicistat with any ritonavir-boosted protease inhibitor (including saquinavir, which must be used with ritonavir boosting) is not recommended due to the similar CYP3A-inhibiting impact of cobicistat and ritonavir.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; December 2015.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10073":"<p><b>Title</b> Fosamprenavir / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Fosamprenavir. However, the magnitude of this change is unclear, and dosing recommendations for this combination are not available. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of cobicistat with fosamprenavir or any ritonavir-boosted protease inhibitor is not recommended.</p> \n<p><b>Discussion</b> The labeling for cobicistat states that concurrent use of cobicistat with fosamprenavir, saquinavir, or tipranavir is not recommended due to a lack of dosing recommendations.<sup>1</sup> Further, use of cobicistat with any ritonavir-boosted protease inhibitor is not recommended due to the similar CYP3A-inhibiting impact of cobicistat and ritonavir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10074":"<p><b>Title</b> Tipranavir / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Tipranavir. However, the magnitude of this change is unclear, and dosing recommendations for this combination are not available. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of cobicistat with tipranavir or any ritonavir-boosted protease inhibitor is not recommended.</p> \n<p><b>Discussion</b> The labeling for cobicistat states that concurrent use of cobicistat with fosamprenavir, saquinavir, or tipranavir is not recommended due to a lack of dosing recommendations.<sup>1</sup> Further, use of cobicistat with any ritonavir-boosted protease inhibitor is not recommended due to the similar CYP3A-inhibiting impact of cobicistat and ritonavir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10075":"<p><b>Title</b> Ritonavir / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may enhance the therapeutic effect of Ritonavir. Specifically, cobicistat and ritonavir have overlapping effects on the CYP3A4-mediated metabolism of other drugs. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of cobicistat with any regimens containing ritonavir is not recommended.</p> \n<p><b>Discussion</b> The labeling for cobicistat states that concurrent use of cobicistat with any ritonavir-boosted protease inhibitor is not recommended due to the similar CYP3A-inhibiting impact of cobicistat and ritonavir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10076":"<p><b>Title</b> Lovastatin / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Roxithromycin may increase serum concentrations of the active metabolite(s) of Lovastatin. Specifically, concentrations of lovastatin acid may be increased. Roxithromycin may decrease the serum concentration of Lovastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, the concomitant use of roxithromycin (300 mg daily x 5 days) and lovastatin (80 mg single dose) actually decreased the lovastatin AUC and maximum serum concentration (Cmax) 38% and 48%, respectively.<sup>1</sup> The Cmax of lovastatin acid (the active metabolite) increased 38% while the AUC was unchanged.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bucher M, Mair G, Kees F. Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. <i>Eur J Clin Pharmacol</i>. 2002;57(11):787-791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11868800\">[PubMed 11868800]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10077":"<p><b>Title</b> Simvastatin / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Roxithromycin may enhance the adverse/toxic effect of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased simvastatin toxicities if combined with roxithromycin.</p> \n<p><b>Discussion</b> A single case report describes a 73-year-old woman who had been receiving simvastatin 80 mg daily and gemfibrozil 600 mg twice daily for 6 months.<sup>1</sup> Her other medications included ramipril, diltiazem, chlorothiazide and aspirin. Seven days after initiation of roxithromycin for the treatment of an upper respiratory infection, she developed muscle weakness and myalgias and was found to have a serum creatine phosphokinase of 9,800 units/L that subsequently rose to 20,000 units/L.<sup>1</sup> <br><br>Roxithromycin inhibition of CYP3A4 mediated simvastatin metabolism or OATP1B1 mediated simvastatin transport is a possible explanation for the development of rhabdomyolysis in this patient.<sup>2,3,4</sup> However, many other confounding factors likely contributed as well, including the presence of other drugs known to more strongly increase simvastatin exposure (eg, gemfibrozil, diltiazem) and the presence of an acute infection in this patient.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. <i>Intern Med J</i>. 2002;32(9-10):486-490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12380704\">[PubMed 12380704]</a></p>\n<p>2. Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. <i>Eur J Clin Pharmacol</i>. 2006;62(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16416302\">[PubMed 16416302]</a></p>\n<p>3. Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. <i>Eur J Clin Pharmacol</i>. 1994;46(6):551-555. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7995324\">[PubMed 7995324]</a></p>\n<p>4. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. <i>Drug Metab Dispos</i>. 2007;35(5):779-786. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10078":"<p><b>Title</b> Midazolam / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Roxithromycin may increase the serum concentration of Midazolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased midazolam effects/toxicities if combined with roxithromycin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, roxithromycin (300 mg daily x 6 days) increased the midazolam (15 mg single oral dose) AUC, maximum serum concentration, and half-life 47%, 37%, and 29%, respectively.<sup>1</sup> In this study and another analysis, minimal to negligible changes in the pharmacodynamic effects of midazolam were seen when combined with roxithromycin.<sup>2</sup><br><br>Product labeling for roxithromycin states that roxithromycin may prolong or increase the effects of midazolam.<sup>3,4</sup> Additional monitoring for increased midazolam effects/toxicities is recommended.<br><br>The mechanism of this interaction is likely roxithromycin inhibition of CYP3A4, an enzyme responsible for midazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. <i>Eur J Clin Pharmacol</i>. 1994;46(6):551-555. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7995324\">[PubMed 7995324]</a></p>\n<p>2. Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. <i>Pharmacol Toxicol</i>. 1993;73(3):180-185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8265524\">[PubMed 8265524]</a></p>\n<p>3. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>4. Roxemicin (roxithromycin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200410904. Accessed March 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10079":"<p><b>Title</b> Ergot Derivatives / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Roxithromycin may increase the serum concentration of Ergot Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of roxithromycin and ergot derivatives.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine<br><b>Exceptions</b> Cabergoline, Nicergoline, Pergolide</p>\n</div> \n<p><b>Discussion</b> Roxithromycin product labeling states that the combination of roxithromycin and ergot derivatives should be avoided due to the increased risk of ergotism (ie, vasoconstriction, ischemia, necrosis).<sup>1,2</sup> Since no studies have evaluated this combination, this recommendation is based on reports of severe toxicities seen when ergot derivatives were combined with other macrolides, such as erythromycin and clarithromycin.<sup>3,4,5,6</sup> <br><br>Although clarithromycin and erythromycin are more potent CYP3A4 inhibitors than roxithromycin, roxithromycin is a weak CYP3A4 inhibitor and concomitant use may decrease the metabolism of ergot derivatives and lead to increased toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>2. Roxemicin (roxithromycin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200410904. Accessed March 2, 2016.</p>\n<p>3. Francis H, Tyndall A, Webb J. Severe vascular spasm due to erythromycin-ergotamine interaction. <i>Clin Rheumatol</i>. 1984;3(2):243-246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6236021\">[PubMed 6236021]</a></p>\n<p>4. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. <i>Ann Intern Med</i>. 1988;109(3):249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3389610\">[PubMed 3389610]</a></p>\n<p>5. Ghali R, De Lean J, Douville Y, Noel HP, Labbe R. Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy. <i>Ann Vasc Surg</i>. 1993;7(3):291-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8391300\">[PubMed 8391300]</a></p>\n<p>6. Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. <i>Arch Intern Med</i>. 1996;156(4):456-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607732\">[PubMed 8607732]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10080":"<p><b>Title</b> Theophylline Derivatives / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Roxithromycin may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action is required for the majority of patients. Those with theophylline concentrations at or near the upper limit of the therapeutic range or those very sensitive to increases in theophylline concentrations should be monitored more closely if combined with roxithromycin.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline<br><b>Exception</b> Dyphylline</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, roxithromycin (150 mg twice daily x 5 days) increased theophylline (200 mg three times daily x 5 days) AUC, maximum serum concentration and half-life 16%, 15%, and 8%, respectively.<sup>1</sup> In a study of 16 patients hospitalized for bronchitis, roxithromycin (150 mg twice daily) administered 4 days after theophylline (300 mg sustained release twice daily) initiation resulted in a 14% increase in theophylline trough concentrations.<sup>2</sup> In contrast, in a pharmacokinetic study of 5 healthy volunteers, roxithromycin (300 mg twice daily x 5 days) had no effect on the pharmacokinetic parameters of theophylline (200 mg sustained release twice daily).<sup>3</sup><br><br>Product labeling for roxithromycin states that roxithromycin may increase theophylline serum concentrations slightly, but theophylline dose adjustments are usually not needed.<sup>4,5</sup><br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. <i>J Antimicrob Chemother</i>. 1987;20(suppl B):121-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3429380\">[PubMed 3429380]</a></p>\n<p>2. Bandera M, Fioretti M, Rimoldi R, Lazzarini A, Anelli M. Roxithromycin and controlled release theophylline, an interaction study. <i>Chemioterapia</i>. 1988;7(5):313-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3224399\">[PubMed 3224399]</a></p>\n<p>3. Hashiguchi K, Niki Y, Soejima R. Roxithromycin does not raise serum theophylline levels. <i>Chest</i>. 1992;102(2):653-654. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1643975\">[PubMed 1643975]</a></p>\n<p>4. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>5. Roxemicin (roxithromycin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200410904. Accessed March 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10081":"<p><b>Title</b> Cyclophosphamide / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Roxithromycin may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk for hepatic venoocclusive disease may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of hepatic venoocclusive disease if roxithromycin is combined with cyclophosphamide.</p> \n<p><b>Discussion</b> A single case report describes a 66-year-old woman who was initiated on both roxithromycin (600 mg daily) and cyclophosphamide (100 mg daily) for the treatment of a respiratory infection and a flare of her autoimmune hemolytic anemia.<sup>1</sup> Five days later she developed jaundice, right upper quadrant pain, and elevated liver enzymes. A transjugular liver biopsy revealed hepatic venoocclusive disease. Symptoms subsided and liver enzymes normalized 2 months after cyclophosphamide discontinuation.<sup>1</sup><br><br>The mechanism of this interaction is unknown. CYP3A4 inhibition by roxithromycin leading to increased metabolism by CYP2B6, the enzyme responsible for cyclophosphamide activation (which would increase effects/toxicities), has been proposed,<sup>1</sup> but a separate in vitro study suggests roxithromycin may inhibit both CYP3A4 and CYP2B6 mediated cyclophosphamide metabolism.<sup>2</sup> Other proposed mechanisms include roxithromycin inhibition of P-glycoprotein or a pharmacodynamic interaction by which roxithromycin may cause cells to be more sensitive to the apoptotic effects of cyclophosphamide.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beltinger J, Haschke M, Kaufmann P, Michot M, Terracciano L, Krahenbuhl S. Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. <i>Ann Pharmacother</i>. 2006;40(4):767-770. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16595573\">[PubMed 16595573]</a></p>\n<p>2. Kaufmann P, Haschke M, Torok M, et al. Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. <i>Ther Drug Monit</i>. 2008;28(6):766-774. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17164692\">[PubMed 17164692]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10082":"<p><b>Title</b> Astemizole / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Roxithromycin may enhance the QTc-prolonging effect of Astemizole. Roxithromycin may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of roxithromycin and astemizole.</p> \n<p><b>Discussion</b> Roxithromycin product labeling states that the combination of roxithromycin and astemizole should be avoided due to the increased risk of QTc prolongation.<sup>1,2</sup> Although no studies have evaluated this combination, roxithromycin is a weak CYP3A4 inhibitor and may decrease the metabolism of astemizole. Because both agents have also been independently associated with QTc prolongation, their combined use may result in additive QTc prolonging effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>2. Roxemicin (roxithromycin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200410904. Accessed March 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10083":"<p><b>Title</b> Warfarin / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Roxithromycin may enhance the anticholinergic effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (eg, increased international normalized ration [INR], bleeding) if combined with roxithromycin.</p> \n<p><b>Discussion</b> In a study of 21 healthy volunteers stabilized on warfarin therapy, 10 subjects were randomized to receive roxithromycin (150 mg twice daily) with their warfarin therapy for 14 days and 11 subjects received placebo.<sup>1</sup> At the end of the study, the mean change in warfarin AUC did not differ between groups and the ratio of S-warfarin to R-warfarin also remained similar between groups.<sup>1</sup> No differences in coagulation parameters were noted between groups and there were no episodes of bleeding.<sup>1</sup><br><br>Despite the lack of roxithromycin effect on warfarin pharmacokinetics in this study, product labeling for roxithromycin states that elevated INRs and severe bleeding episodes have been reported in patients treated concomitantly with warfarin and roxithromcyin.<sup>2,3</sup> Increased INR monitoring is recommended.<br><br>The mechanism of this potential interaction has not been established, but roxithromycin inhibition of CYP3A4, an enzyme responsible for R-warfarin metabolism, may play a role.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Paulsen O, Nilsson LG, Saint-Salvi B, Manuel C, Lunell E. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. <i>Pharmacol Toxicol</i>. 1988;63(4):215-220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3194342\">[PubMed 3194342]</a></p>\n<p>2. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>3. Roxemicin (roxithromycin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200410904. Accessed March 2, 2016.</p>\n<p>4. Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. <i>Drug Metab Dispos</i>. 1998;26(11):1053-1057. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9806945\">[PubMed 9806945]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10084":"<p><b>Title</b> Roxithromycin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Roxithromycin. Roxithromycin may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 heart transplant recipients who were receiving stable cyclosporine doses for at least 1 month, addition of roxithromycin (150 mg twice daily x 11 days) increased the mean cyclosporine trough concentrations 45%.<sup>1</sup> No cyclosporine dose adjustments were needed and no changes in renal function were observed during the study.<sup>1</sup><br><br>In another study, roxithromycin (300 mg) was administered to 9 cyclosporine-treated transplant recipients, 10 azathioprine-treated transplant recipients, and 6 healthy volunteers.<sup>2</sup> In cyclosporine treated patients, the roxithromycin AUC was 1.5-fold and 2.2-fold higher than in azathioprine treated patients and healthy volunteers, respectively.<sup>2</sup><br><br>Product labeling for roxithromycin states that roxithromycin may increase cyclosporine serum concentrations slightly, but cyclosporine dose adjustments are usually not needed.<sup>3,4</sup><br><br>The mechanism by which roxithromycin may increase cyclosporine concentrations is likely due to roxithromycin inhibition of CYP3A4 and/or P-glycoprotein, an enzyme and transporter responsible for cyclosporine metabolism and transport. The mechanism by which cyclosporine may increase roxithromycin concentrations may relate to cyclosporine inhibition of CYP3A4 or P-glycoprotein, or cyclosporine-induced renal damage leading to reduced roxithromycin clearance may play a role.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. <i>Clin Pharmacokinet</i>. 1990;19(6):499-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2292171\">[PubMed 2292171]</a></p>\n<p>2. Moravek J, Matousovic K, Prat V, Sedivy J. Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(6):262-267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2376427\">[PubMed 2376427]</a></p>\n<p>3. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>4. Roxemicin (roxithromycin) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200410904. Accessed March 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10086":"<p><b>Title</b> Cardiac Glycosides / Roxithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Roxithromycin may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased cardiac glycoside serum concentrations and effects (eg, nausea, vomiting, bradycardia, ECG changes) if combined with roxithromycin.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> One case report describes a 76-year-old woman who had been taking digoxin (0.25 mg daily) for approximately 1 year.<sup>1</sup> Four days after the initiation of roxithromycin (150 mg twice daily) she developed nausea, vomiting, and general malaise.<sup>1</sup> Her electrocardiogram (ECG) revealed a prolonged PR interval, ST segment changes consistent with digoxin toxicity and a digoxin serum level of 7.5 nmol/L.<sup>1</sup> Her serum digoxin level 4 months prior to this presentation was 1.7 nmol/L.<sup>1</sup><br><br>Product labeling for roxithromycin states that a study of healthy volunteers has shown that roxithromycin may increase the absorption of digoxin.<sup>2</sup> No details of the study are provided, but increased monitoring of digoxin and other cardiac glycosides is recommended when combined with roxithromycin.<sup>2</sup><br><br>The mechanism of this interaction is unknown, but roxithromycin inhibition of P-glycoprotein, a transporter responsible for digoxin transport, may play a role.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Corallo CE, Rogers IR. Roxithromycin-induced digoxin toxicity. <i>Med J Aust</i>. 1996;165(8):433-434. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8913245\">[PubMed 8913245]</a></p>\n<p>2. Rulide (roxithromycin) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; January 2015.</p>\n<p>3. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. <i>J Pharmacol Sci</i>. 2010;113(4):315-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20724802\">[PubMed 20724802]</a></p>\n<p>4. Munic V, Kelneric Z, Mikac L, Erakovic Haber V. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. <i>Eur J Pharm Sci</i>. 2010;41(1):86-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20621639\">[PubMed 20621639]</a></p>\n<p>5. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. <i>Clin Pharmacokinet</i>. 2007;46(12):1039-1049. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18027988\">[PubMed 18027988]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10088":"<p><b>Title</b> Distigmine / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may diminish the therapeutic effect of Distigmine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response to distigmine closely if concurrent administration of an aminoglycoside antibiotics is required.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The distigmine summary of product characteristics cautions that aminoglycoside antibiotics may worsen neuromuscular conduction, possibly decreasing the effects of distigmine.<sup>1</sup><br><br>Aminoglycosides possess some measure of neuromuscular-blocking activity which varies from one agent to another. When combined with neuromuscular-blocking agents, the respiratory depressant effects have been greater and longer.<sup>2,3,4,5,6,7</sup> The effects appear to manifest regardless of the route of aminoglycoside administration, including parenteral, oral, intraperitoneal, intraplural, and beneath skin flaps. The mechanism of these interactions is presumably due to an additive and/or synergistic effect on muscular tone. Aminoglycoside-induced neuromuscular-blockade may be dose-related.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ubretid (distigmine) [summary of product characteristics]. Austria: Takeda Pharmaceuticals (Asia Pacific) PTE. LTD.; March 2015.</p>\n<p>2. Warner WA, Sanders E. Neuromuscular-blockade associated With gentamicin therapy. <i>JAMA</i>. 1971;215(7):1153-1154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4250687\">[PubMed 4250687]</a></p>\n<p>3. Levanen J, Nordman R. Complete respiratory paralysis caused by a large dose of streptomycin and its treatment with calcium chloride. <i>Ann Clin Res</i>. 1975;7(1):47-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1155911\">[PubMed 1155911]</a></p>\n<p>4. Holtzman JL. Gentamicin and neuromuscular blockade. <i>Ann Intern Med</i>. 1976;84(1):55-56 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1244797\">[PubMed 1244797]</a></p>\n<p>5. Boliston TA, Ashman R. Tobramycin neuromuscular blockade. <i>Anaesthesia</i>. 1978;33(6):552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=686321\">[PubMed 686321]</a></p>\n<p>6. Jedeikin R, Dolgunski E, Kaplan R, et al. Prolongation of neuromuscular-blocking effect of vecuronium by antibiotics. <i>Anaesthesia</i>. 1987;42(8):858-860. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2889390\">[PubMed 2889390]</a></p>\n<p>7. Giala M, Sareyiannis C, Cortsaris N, et al. Possible interaction of pancuronium and tubocurarine with oral neomycin. <i>Anaesthesia</i>. 1982;37(7):776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7103026\">[PubMed 7103026]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10089":"<p><b>Title</b> CNS Stimulants / Acebrophylline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Acebrophylline may enhance the stimulatory effect of CNS Stimulants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> CNS stimulants should not be coadministered with acebrophylline.</p>\n<div>\n <p><b>CNS Stimulants Interacting Members</b> Amphetamine, Armodafinil, Benzphetamine, Caffeine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion, Kola Nut, Lisdexamfetamine, Methamphetamine, Methylphenidate, Modafinil, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> According to the acebrophylline labeling, concurrent use of CNS stimulants or other xanthine derivatives (e.g., theophylline, etc.) with acebrophylline may result in excessive CNS stimulation. The combination should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Acebrophylline 100 mg capsule [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199803076. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10090":"<p><b>Title</b> Reserpine / Acebrophylline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acebrophylline may enhance the tachycardic effect of Reserpine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that concurrent use of acebrophylline with reserpine may result in tachycardia. Monitor patient response to the combination closely.</p> \n<p><b>Discussion</b> The acebrophylline labeling states that concurrent use of acebrophylline with reserpine may result in tachycardia.<sup>1</sup> The specific mechanism of this interaction is likely additive tachycardic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Acebrophylline 100 mg capsule [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199803076. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10091":"<p><b>Title</b> Furosemide / Acebrophylline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acebrophylline may enhance the therapeutic effect of Furosemide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that concurrent use of acebrophylline with furosemide may result in increased diuresis. Monitor patient response to the combination closely.</p> \n<p><b>Discussion</b> The acebrophylline labeling states that concurrent use of acebrophylline with furosemide may result in increased diuresis.<sup>1</sup> The specific mechanism of this interaction is likely additive diuretic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Acebrophylline 100 mg capsule [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199803076. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10092":"<p><b>Title</b> Theophylline Derivatives / Acebrophylline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Acebrophylline may enhance the stimulatory effect of Theophylline Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Other theophylline derivatives or CNS stimulants should not be coadministered with acebrophylline.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> According to the acebrophylline labeling, concurrent use of CNS stimulants or other xanthine derivatives (e.g., theophylline, etc.) with acebrophylline may result in excessive CNS stimulation. The combination should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Acebrophylline 100 mg capsule [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199803076. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10093":"<p><b>Title</b> Anthracyclines / Ado-Trastuzumab Emtansine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ado-Trastuzumab Emtansine may enhance the cardiotoxic effect of Anthracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Anthracycline-based therapy should be avoided if possible for up to 7 months after discontinuation of ado-trastuzumab emtansine. Frequent monitoring for signs and symptoms of cardiac dysfunction in patients receiving anthracyclines plus trastuzumab must be conducted. If evidence of heart failure develops, consideration should be given to discontinuing ado-trastuzumab emtansine therapy.</p>\n<div>\n <p><b>Anthracyclines Interacting Members</b> DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, IDArubicin</p>\n</div> \n<p><b>Discussion</b> All data related to this potential drug interaction are the result of studies with trastuzumab. Since ado-trastuzumab emtansine contains trastuzumab, the data and management recommendations for this interaction likely apply to both products. Phase 2 trials provide evidence that the incidence of cardiotoxicity associated with coadministration of trastuzumab, cyclophosphamide, and an anthracycline (28%) is greater than that of either trastuzumab alone (7%) or the combination of a cyclophosphamide and an anthracycline (7%).<sup>1</sup> In another study, when ado-trastuzumab emtansine was administered after completion of anthracycline based chemotherapy, the incidence of cardiotoxicity was 3.4%.<sup>2</sup> Coadministration of ado-trastuzumab emtansine and anthracycline therapy was not evaluated.<sup>2</sup> <br><br>The mechanism of trastuzumab cardiotoxicity is unclear; however, it appears to be different from, and synergistic with, anthracyclines. HER2 proteins (receptors) are not only expressed in some breast carcinomas, but also in cardiac tissue.<sup>3,4</sup> The implications of blocking HER2 receptors in the heart are unclear. A pharmacokinetic study revealed no effects of trastuzumab on epirubicin AUC.<sup>5</sup> Trastuzumab-related cardiotoxicity, unlike that induced by anthracyclines, usually responds to therapy discontinuation and/or standard heart failure treatments.<sup>6</sup><br><br>The trastuzumab prescribing information recommends that patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab based on the long wash-out period for trastuzumab.<sup>1</sup> It is reported that approximately 97% of trastuzumab is removed by 7 months after cessation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Herceptin (trastuzumab) [prescribing information]. South San Francisco, CA: Genetech Inc; April 2015.</p>\n<p>2. Krop IE, Suter TM, Dang CT, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. <i>J Clin Oncol</i>. 2015;33(10:1136-1142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25713436\">[PubMed 25713436]</a></p>\n<p>3. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. <i>Science</i>. 1992;256(5060):1205-1210. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1350381\">[PubMed 1350381]</a></p>\n<p>4. Rohrbach S, Yan X, Weinberg EO, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. <i>Circulation</i>. 1999;100(4):407-412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10421602\">[PubMed 10421602]</a></p>\n<p>5. Lunardi G, Vannozzi MO, Bighin C, et al. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. <i>Ann Oncol</i>. 2003;14(8):1222-1226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12881383\">[PubMed 12881383]</a></p>\n<p>6. Keefe DL. Trastuzumab-associated cardiotoxicity. <i>Cancer</i>. 2002;95(7):1592-1600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12237930\">[PubMed 12237930]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10094":"<p><b>Title</b> Bupivacaine (Liposomal) / Bupivacaine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bupivacaine may enhance the adverse/toxic effect of Bupivacaine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Bupivacaine may be administered immediately before, or in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2. Greater concentrations of bupivacaine may affect the pharmacokinetics or physiochemical properties of liposomal bupivacaine. Additionally, since the toxic effects of these drugs are additive, their administration should be done with caution and patients should be monitored for neurologic and cardiovascular toxicities.</p> \n<p><b>Discussion</b> Prescribing information for liposomal bupivacaine states that bupivacaine administered with liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of liposomal bupivacaine, and this effect is concentration dependent.<sup>1</sup> Therefore, bupivacaine may be administered immediately before or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2.<sup>1</sup> Patients should be monitored for additive neurologic and cardiovascular toxicities if these agents are combined.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Exparel (liposomal bupivacaine) [prescribing information]. San Diego, CA: Pacira Pharmaceuticals Inc; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10095":"<p><b>Title</b> Bupivacaine (Liposomal) / Local Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Liposomal bupivacaine should not be administered with local anesthetics as this may cause an immediate release of bupivacaine from the liposomal product. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown.</p>\n<div>\n <p><b>Local Anesthetics Interacting Members</b> Articaine, Benoxinate, Bupivacaine, Bupivacaine (Liposomal), Chloroprocaine, Levobupivacaine, Lidocaine (Systemic), Mepivacaine, Prilocaine, Procaine, Ropivacaine, Tetracaine (Systemic)<br><b>Exceptions</b> Benzocaine, Benzydamine, Cocaine (Topical), Dibucaine, Dyclonine, Ethyl Chloride, Hexylresorcinol, Lidocaine (Ophthalmic), Lidocaine (Topical), Pramoxine, Proparacaine, Tetracaine (Ophthalmic), Tetracaine (Topical)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for liposomal bupivacaine states that liposomal bupivacaine should not be admixed or administered with local anesthetics other than bupivacaine.<sup>1</sup> Nonbupivacaine based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from the liposomal product if administered together locally.<sup>1</sup> The administration of liposomal bupivacaine may follow the administration of lidocaine after a delay of 20 minutes or more.<sup>1</sup> Specific dose separation recommendations for other local anesthetics are not provided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Exparel (liposomal bupivacaine) [prescribing information]. San Diego, CA: Pacira Pharmaceuticals Inc; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10096":"<p><b>Title</b> Bupivacaine (Liposomal) / Lidocaine (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction specifically applies to the use of lidocaine as a local anesthetic.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lidocaine (Systemic) may enhance the adverse/toxic effect of Bupivacaine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Liposomal bupivacaine should not be administered with lidocaine as this may cause an immediate release of bupivacaine from the liposomal product if they administered together locally. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine.</p> \n<p><b>Discussion</b> Prescribing information for liposomal bupivacaine states that liposomal bupivacaine should not be admixed or administered with local anesthetics other than bupivacaine.<sup>1</sup> Nonbupivacaine based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from the liposomal product if administered together locally.<sup>1</sup> The administration of liposomal bupivacaine may follow the administration of lidocaine after a delay of 20 minutes or more.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Exparel (liposomal bupivacaine) [prescribing information]. San Diego, CA: Pacira Pharmaceuticals Inc; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}